Document:

EX-10.6

 Exhibit 10.6 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT
THE 
 REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. 

LICENSE AGREEMENT FOR RAF 

This LICENSE AGREEMENT FOR RAF (the “Agreement”), effective as of December 16, 2019 (the “Effective
Date”), is made by and between Sunesis Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (“Sunesis”), and DOT Therapeutics-1, Inc., a Delaware corporation, having a principal place of business at 2765 Sand Hill Road, Menlo Park, CA 94025 (“DOT-1”). Sunesis and DOT-1 are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

BACKGROUND 
 A. Sunesis
has developed proprietary technology and know-how for the discovery and optimization of small molecules that bind to enzyme targets and protein-protein interfaces, with special expertise towards kinases. 

B. On December 16, 2019, Millennium transferred Millennium’s, and its Affiliates’, rights to certain Licensed Products to DOT-1 (such transaction, the “Program Transfer”). As part of the Program Transfer, Millennium Pharmaceuticals, Inc. (“Millennium”) assigned to
DOT-1 that certain Amended and Restated License Agreement for Raf between Millennium and Sunesis, dated December 13, 2019 (the “Raf Agreement”). 

C. Coincident with the completion of the Program Transfer, DOT-1 and Sunesis now desire to amend and
restate the Raf Agreement in its entirety to incorporate certain terms agreed between the Parties, on the terms and conditions set forth below. 

NOW, THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, it is agreed by and between the
Parties as follows: 
 ARTICLE 1 

DEFINITIONS 
 As used
herein, the following terms will have the meanings set forth below: 
 1.1 “Affiliate” of a Person shall mean any
corporation or other business entity that during the Term of this Agreement controls, is controlled by or is under common control with such Person but only for so long as such entity controls, is controlled by, or is under common control with such
Person. With respect to a particular entity, “control” shall mean the ownership directly or indirectly of fifty percent (50%) or more of the stock entitled to vote for the election of directors, and for nonstock organizations, of the
equity interests entitled to control the management of such entity. 

 1.2 “BLA” shall mean a Biologics License Application (or its equivalent),
as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding or similar application, registration or certification in any jurisdiction for marketing authorization of a biologic product. 

1.3 “CDA” means the Mutual Confidential Disclosure Agreement by and between Sunesis and
DOT-1 dated June 9, 2019. 
 1.4 “Collaboration Technology” means the
Collaboration Patents and the Collaboration Know-How. 
 1.4.1 “Collaboration
Patents” means all DOT-1 Collaboration Patents, Joint Collaboration Patents and Sunesis Collaboration Patents. 

1.4.2 “Collaboration Know-How” means all DOT-1 Collaboration Know- How, Joint Collaboration Know-How and Sunesis Collaboration Know-Know. 

1.5 “Combination Product” shall mean any of (i) a Licensed Product that incorporates two or more active drug substances
including a Licensed Compound, or (ii) a Reverted Licensed Product that incorporates two or more active drug substances including a Reverted Compound; in each case where at least one of the active drug substances is not a Licensed Compound or
Reverted Compound, respectively. 
 1.6 “Commercially Reasonable and Diligent Efforts” shall mean (a) the level of
effort and resources normally used by a Party for a product or compound owned or controlled by it, which is of similar market potential and at a similar stage in its development or product life, taking into account, without limitation, with respect
to a product issues of safety and efficacy, product profile, the proprietary position of the product, the then current competitive environment for the product and the likely timing of the product’s entry into the market, the regulatory
environment of the product, and other relevant scientific, technical and commercial factors (such product, a “Similar Product”) or (b) if the relevant Party does not have a Similar Product, then the level of effort and resources
normally used by pharmaceutical companies of similar size and resources in their reasonable, good faith efforts to accomplish such objective, activity, or decision with respect to Similar Products. Notwithstanding the foregoing, to the extent that
the performance of a Party’s responsibilities hereunder is adversely affected by the other Party’s failure to perform its responsibilities hereunder, such Party shall not be deemed to have failed to use its Commercially Reasonable and
Diligent Efforts in performing such responsibilities. 
 1.7 “Confidential Information” shall mean, with respect to a
Party, all information (and all tangible and intangible embodiments thereof), which is owned or controlled by such Party, and is or was disclosed by such Party to the other Party pursuant to the CDA or this Agreement. Notwithstanding the foregoing,
Confidential Information of a Party shall not include information which, and only to the extent, the receiving Party can establish by written documentation (a) has been generally known prior to disclosure of such information by the disclosing
Party to the receiving Party; (b) has become generally known, without the fault of the receiving Party, subsequent to disclosure of such information by the disclosing Party to the receiving Party; (c) has been received by the receiving
Party at any time from a source, other than the disclosing Party, 

  
 2 

 
rightfully having possession of and the right to disclose such information free of confidentiality obligations; (d) has been otherwise known by the receiving Party free of confidentiality
obligations prior to disclosure of such information by the disclosing Party to the receiving Party; or (e) is independently developed without reference to or use of the Confidential Information of the disclosing Party. For clarity, except as
otherwise expressly provided in this Agreement, Joint Collaboration Technology shall be deemed Confidential Information of both DOT-1 and Sunesis; DOT-1 Collaboration
Technology and Development Technology shall, be deemed Confidential Information solely of DOT-1; and the Sunesis Collaboration Technology and Sunesis Licensed Technology shall be deemed Confidential
Information solely of Sunesis. 
 1.8 “Control” or “Controlled” shall mean, with respect to any Patent
Rights or Know- how and with respect to any Person, possession (whether by ownership or license, other than a license granted pursuant to this Agreement) by such Person or its Affiliate of the ability to grant the licenses or sublicenses as provided
for herein without violating the terms of any agreement or other arrangement with any Third Party. 
 1.9 “Development”
shall mean all research, development and regulatory activities regarding the Licensed Products. “Development” shall include all activities related to research, optimization and design of the appropriate molecule and identification of back-ups, preclinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and
validation, quality assurance/quality control, clinical studies, manufacturing clinical supplies, regulatory affairs, statistical analysis and report writing, technology transfer, market research and development, and all other pre-approval and related post-approval activities. When used as a verb, “Develop” shall mean to engage in Development. 

1.10 Reserved. 
 1.11
Reserved. 
 1.12 “Development Technology” shall mean any Know-How that is
made or developed by or under authority of DOT-1 or its Affiliates, whether alone or jointly with others, in the course of performing any activity under this Agreement that is directed to the Raf Target or
directly related to the Development, manufacturing or commercialization of a Licensed Compound or Licensed Product, and all Patent Rights that claim or cover any such Know-How. 

1.13 “Diligence Summary” shall mean, with respect to a particular Product, a summary of Development and commercialization
activities with respect to such Product, that (i) were performed by the reporting Party or its Third Party collaborators in the previous [*] period (or shorter period from the prior Diligence Summary, if applicable), and (ii) as of the
date of the Diligence Summary, are planned in good faith for the following [*] period. For clarity, it is understood and acknowledged that in providing a Diligence Summary, a Party shall not be required to disclose scientific results, specific
research activities or the identity of any Third Party collaborator or potential collaborator. 

  
 3 

 1.14 “DOT-1 Collaboration
Technology” shall mean all DOT-1 Collaboration Patents and DOT-1 Collaboration Know-How. 

1.14.1 “DOT-1 Collaboration Patents” shall mean DOT-1’s interest in those Patent Rights set forth on or claiming priority to those listed on, Exhibit 1.14. Notwithstanding the foregoing, DOT-1 Collaboration
Patents shall in all cases exclude Joint Collaboration Patents. 
 1.14.2
“DOT-1 Collaboration Know-How” shall mean DOT-1’s interest in all
Know-How that was made or developed after August 27, 2004 but prior to the Effective Date and is specifically related to the Raf Target or to the discovery, research, or development of Licensed Compounds
or Licensed Products; such Know-How is set forth on Exhibit 1.14. Notwithstanding the foregoing, DOT-1 Collaboration
Know-How shall in all cases exclude Joint Collaboration Know-How. 

1.15 “Field” shall mean the treatment, prevention or diagnosis of disease in humans and animals. 

1.16 “Governmental Authority” shall mean any multi-national, federal, state, local, municipal or other government authority
of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). 

1.17 “Gross Sales” shall mean the gross amount [*]. 

1.18 “Joint Collaboration Technology” shall mean all Joint Collaboration Patents and Joint Collaboration Know-How. 
 1.18.1 “Joint Collaboration Patents” shall mean all Patent
Rights set forth on, or claiming priority to those listed on, Exhibit 1.18. 
 1.18.2 “Joint Collaboration Know-How” shall mean all Know-How that was made or developed after August 27, 2004 but prior to March 31, 2011 in the course of activities specifically
related to the Raf Target or to the discovery, research, or development of Licensed Compounds or Licensed Products that is set forth on Exhibit 1.18. Notwithstanding the foregoing, Joint Collaboration
Know-How shall in all cases exclude Sunesis Collaboration Patents. 
 1.19 “Know-How” shall mean any data, inventions, invention disclosures, methods, proprietary information, processes, techniques, technology, or material (including biological or other materials). 

1.20 “Licensed Compounds” shall mean (i) BIIB024 (also referred to as TAK-580),
and (ii) all other compounds claimed or covered by a Collaboration Patent that are directed to the Raf Target (including Collaboration Patents listed in Exhibits 1.14, 1.18 and 1.37 attached hereto, which have been
updated as of the Effective Date), (iii) all other compounds claimed or covered by an invention disclosure within the Collaboration Know-How that are directed to the Raf Target, and (iv) all salts,
prodrugs, esters, metabolites, solvates, stereoisomers and polymorphs of any of the foregoing. 

  
 4 

 1.21 “Licensed Product” shall mean a pharmaceutical preparation for sale by
prescription, over-the-counter, or any other method for all uses in humans or animals, which incorporates one or more Licensed Compounds as an active drug substance, but
excluding Reverted Licensed Products. It is understood that Licensed Products containing different active ingredient(s) (i.e., a different active ingredient or an additional active ingredient) or a different formulation shall be deemed different
“Licensed Products”. 
 1.22 “NDA” shall mean a New Drug Application (or its equivalent), as defined in the U.S.
Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding or similar application, registration or certification in any jurisdiction for marketing authorization of a product. 

1.23 “Net Consideration” shall mean, with respect to the sale of a PRV by DOT-1 or
its Affiliate or Sublicensee (the “Seller”), an amount equal to [*]. 
 1.24 “Net Sales” shall mean, with respect
to a Product, Gross Sales less applicable Sales Returns and Allowances. 
 [*]. 

1.25 “Patent Rights” shall mean all patents and patent applications in any country in the world, including any continuations,
continuations-in-part, divisionals, provisionals or any substitute applications, any patent issued with respect to any such patent applications, any reissue,
reexamination, renewal or extension (including any supplemental protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent. 

1.26 “Person” shall mean any natural person, corporation, general partnership, limited partnership, joint venture,
proprietorship or other business organization or a Governmental Authority. 
 1.27 “Phase I” shall mean human clinical
trials, the principal purpose of which is the preliminary evaluation of safety in healthy individuals as more fully defined in 21 C.F.R. §312.21(a) or similar clinical study in a country other than the United States. An initial study in
patients where the primary purpose is the preliminary evaluation of safety will be considered a Phase I study. 
 1.28 “Phase
II” shall mean human clinical trials conducted on a limited number of patients for the primary purpose of evaluation of both clinical efficacy and safety, or to obtain a preliminary evaluation of the dosage regimen, as more fully defined in
21 C.F.R. §312.21(b). 
 1.29 “Phase III” shall mean human clinical trials, the principal purpose of which is to
establish substantial evidence of both safety and efficacy in patients with the disease or condition being studied, as more fully defined in 21 C.F.R. §312.21(c) or similar clinical study in a country other than the United States. Phase III
shall also include any other human clinical trial intended to serve as a pivotal trial to support the submission of an application for regulatory approval. 

  
 5 

 1.30 “Product” shall mean a Licensed Product or Reverted Licensed Product,
as applicable. 
 1.31 “PRV” shall mean a rare pediatric disease priority review voucher granted by the FDA with respect to
a Licensed Product pursuant to Section 529 of the Federal Food Drug and Cosmetic Act or the successor thereto. 
 1.32 “Raf
Target” shall mean the human Raf protein together with the Raf protein family members Raf-1, A-Raf, B-Raf and C-Raf. 
 1.33 “Regulatory Approval” shall mean approval of the health regulatory agency
in a country (FDA in the U.S. and comparable authority outside the U.S.) necessary for the marketing and sale of a product in the applicable country. As used herein, “Regulatory Approval” shall not include pricing or reimbursement
approval. 
 1.34 “Reverted Compound” shall mean, with respect to a Reverted Licensed Product, any Licensed Compound
included in such Reverted Licensed Product. 
 1.35 “Sales Returns and Allowances” shall mean, with respect to a specific
Product, the sum of (a) and (b), where: (a) [*]; and (b) [*]. 
 1.36 “Sublicensee” shall mean a Third Party expressly
licensed by a Party or its Affiliate to make, use, import, offer for sale or sell a Product. The term “Sublicensee” shall not include distributors (i.e., a Third Party who purchases Product from a Party for resale). 

1.37 “Sunesis Collaboration Technology” shall mean all Sunesis Collaboration Patents and Sunesis Collaboration Know-How. 
 1.37.1 “Sunesis Collaboration Patents” shall mean
(a) those Patent Rights set forth on or claiming priority to those listed on, Exhibit 1.37. Notwithstanding the foregoing, Sunesis Collaboration Patents shall in all cases exclude Joint Collaboration Patents. 

1.37.2 “Sunesis Collaboration Know-How” shall mean any Know-How made or developed solely by or under authority of personnel of Sunesis or any of its controlled Affiliates, after August 27, 2004 but prior to March 31, 2011, in the course of activities
specifically related to the Raf Target or to the discovery, research, or development of Licensed Compounds or Licensed Products. Notwithstanding the foregoing, Sunesis Collaboration Know-How shall in all cases
exclude Joint Collaboration Know-How. 
 1.38 “Sunesis Licensed Technology” shall
mean Sunesis Licensed Patents and Sunesis Licensed Know-How. For clarity, the Sunesis Licensed Technology shall include Sunesis’ interest in the Joint Collaboration Technology and the Sunesis
Collaboration Technology. 
 1.38.1 “Sunesis Licensed Patents” shall mean (i) Sunesis’s interest
in Collaboration Patents, (ii) all Patent Rights Controlled by Sunesis as of March 31, 2011 or the Effective Date that claim or cover the Raf Target, Licensed Compounds or Licensed Products, and (iii) all Patent Rights that arise
during the Term that claim or cover any Know- How Controlled by Sunesis (a) as of March 31, 2011 that relates to the Raf Target 

  
 6 

 
or a Licensed Compound or Licensed Product or (b) as of the Effective Date that was made or developed in the course of activities specifically related to the research or development of
Licensed Compounds or Licensed Products. The Sunesis Licensed Patents as of the Effective Date are listed in Exhibit 1.38. 

1.38.2 “Sunesis Licensed Know-How” shall mean (i) Sunesis
Collaboration Know-How, (ii) Sunesis’s interest in Joint Collaboration Know-How, and (iii) any Know-How Controlled
by Sunesis (a) as of March 31, 2011 that relates to the Raf Target, Licensed Compound or Licensed Product or (b) as of the Effective Date that was made or developed in the course of activities specifically related to the research or
development of Licensed Compounds or Licensed Products. 
 1.39 “Target Selective” shall mean, when used to describe a
chemical compound with respect to the Raf Target, that such compound exhibits [*] cell-based assay, and [*] (i) [*] enzyme assay ([*]) or (ii) [*]. For the purposes of the foregoing, the relevant cell-based and enzyme assays shall be as specified in
Exhibit 1.39 and the [*] in (ii) shall be measured in the same enzyme assay as (i). 
 1.40 “Third Party” shall mean
any person or entity other than Sunesis and DOT-1, and their respective Affiliates. 
 1.41
“Valid Claim” shall mean (i) a claim of an issued and unexpired patent (or the equivalent in a supplementary protection certificate), including any patent term extensions of such patent, which has not lapsed or become abandoned
or been declared invalid or unenforceable by a court of competent jurisdiction or an administrative agency from which no appeal can be or is taken or (ii) a claim of a pending patent application, filed in good faith, which claim shall not have
been canceled, withdrawn, abandoned or rejected by an administrative agency from which no appeal can be taken; provided that no more than [*] has passed since the filing date for such patent application. 

1.42 Construction. In construing this Agreement, unless expressly specified otherwise: 

1.42.1 references to Sections, Articles and Exhibits are to sections and articles of, and exhibits to, this Agreement; 

1.42.2 except where the context otherwise requires, use of any gender includes any other gender, and use of the singular
includes the plural and vice versa; 
 1.42.3 any list or examples following the word “including” shall be
interpreted without limitation to the generality of the preceding words; 
 1.42.4 except where the context otherwise
requires, the word “or” is used in the inclusive sense; and 
 1.42.5 all references to “dollars” or
“$” herein shall mean U.S. Dollars. 

  
 7 

 1.43 Additional Terms. In addition to the foregoing, the following terms shall have
the meaning defined in the corresponding Section below: 
  

			
	Defined Term	 	Section
	Agreement	 	Preamble
	Annual Net Sales	 	6.3.1
	ATLA	 	5.1.2
	Competing Program	 	15.3
	Controlling Party	 	9.3.4
	Cooperating Party	 	9.3.4
	Diligence Failure	 	8.2.1
	DOT-1	 	Preamble
	Effective Date	 	Preamble
	Indemnitee	 	12.3
	Indemnitor	 	12.3
	Indication	 	6.2.2(b)
	Infringement Action	 	9.3.4
	Liabilities	 	12.1
	Millennium	 	Background
	Millennium Option	 	8.2.2
	Millennium Option Period	 	8.2.2
	Millennium Reversion	 	5.1.2
	Millennium Reversion Notice	 	5.1.2
	Option Notice	 	8.2.2
	Other DOT-1 Technology	 	5.1.3
	Other Patent Rights	 	9.2.2
	Party or Parties	 	Preamble
	Program Transfer	 	Background
	Prosecution	 	9.2.2
	Raf Agreement	 	Background
	Reverted Licensed Product	 	8.2.1 and 8.2.2
	Statutory Exclusivity	 	6.3.4
	Subject Infringement	 	9.3.1
	Sunesis	 	Preamble
	Sunesis Reversion License	 	5.1.3
	Term	 	13.1.2
	Transaction Documents	 	11.3.1

 ARTICLE 2 

LICENSED PRODUCT DEVELOPMENT 

2.1 Development by DOT-1. Commencing on the Effective Date,
DOT-1 shall be responsible for undertaking a development program aimed at ultimately seeking Regulatory Approval for Licensed Products. 

2.2 Diligence. DOT-1 shall use Commercially Reasonable and Diligent Efforts to Develop and
obtain Regulatory Approvals for Licensed Products in the Field. 

  
 8 

 2.3 Regulatory Matters. DOT-1 shall file and
be the owner of all regulatory filings for Licensed Compounds or Licensed Products developed pursuant to this Agreement, including all NDAs and Regulatory Approvals, unless otherwise agreed by the Parties. 

ARTICLE 3 
 LICENSED
PRODUCT COMMERCIALIZATION 
 3.1 Commercialization Rights. DOT-1 shall be responsible for
the establishment and implementation of the strategy, plans and budgets for marketing and promotion of the Licensed Products. 
 3.2
Diligence. After receipt of Regulatory Approval for a particular Licensed Product in a particular country, DOT-1 shall use Commercially Reasonable and Diligent Efforts to obtain all necessary pricing or
reimbursement approvals for such Licensed Product in the such country and to commercialize such Licensed Product in the Field in such country. 

ARTICLE 4 
 RESERVED

 ARTICLE 5 

LICENSES 
 5.1
Development and Commercialization Licenses. 
 5.1.1 License under the Sunesis Licensed Technology to Licensed Products.
Subject to the terms and conditions of this Agreement, Sunesis hereby grants to DOT-1 a worldwide, exclusive license under the Sunesis Licensed Technology, with the right to grant and authorize sublicenses as
provided in Section 5.2, to Develop, make, have made, use, import, offer for sale, sell and otherwise exploit Licensed Compounds and Licensed Products in the Field. 

5.1.2 Millennium Reversion. DOT-1 represents and warrants to Sunesis that DOT-1 obtained its interest in the DOT-1 Collaboration Technology, Joint Collaboration Technology and the Raf Agreement from Millennium pursuant to the Program Transfer under
that certain Asset Transfer and License Agreement dated December 16, 2019 (the “ATLA”), and that, in the event of termination of the ATLA, Millennium has (as of the Effective Date) certain rights under the ATLA to receive an
assignment of or license under the DOT-1 Collaboration Technology, Joint Collaboration Technology Development Technology, Other DOT-1 Technology, and related assets
(including DOT-1’s interest in this Agreement) for purposes of developing and commercializing Licensed Compounds and Licensed Products. Accordingly, any and all rights that Sunesis has with respect to
Reverted Licensed Products shall be secondary to Millennium’s reversion rights with respect to such products under the ATLA. If the ATLA terminates and Millennium receives, or exercises its right to receive, an assignment of this Agreement as
well as an assignment of or license under the DOT-1 Collaboration Technology, Joint Collaboration Technology, Development Technology and/or Other DOT-1 Technology to
develop, make, have made, use, import, offer for sale, sell and otherwise exploit such Reverted Licensed Product (collectively, a “Millennium Reversion”), then (a) DOT-1 will provide
Sunesis with prompt written notice of such Millennium Reversion (“Millennium Reversion Notice”) and (b) the license granted to Sunesis in Section 5.1.3 shall not be exercisable, and such Licensed

  
 9 

 
Product shall not become a Reverted Licensed Product, in each case at such time; provided that the license set forth in Section shall apply in the event that a Licensed Product subsequently
becomes a Reverted Licensed Product as set forth in Section 8.2 after such Millennium Reversion occurs. For clarity, the license granted to Sunesis in Section 5.1.3 shall be exercisable and the applicable Licensed Product shall become a
Reverted Licensed Product, in each case without a prior Millennium Reversion, if Millennium exercises the Millennium Option to waive its rights to the Millennium Reversion as contemplated by Section 8.2.2. 

5.1.3 License for Reverted Licensed Products. Subject to the terms and conditions of this Agreement (including Sections 5.1.1 and 5.1.2
above and Section 8.2), with respect to each Reverted Licensed Product, DOT-1 hereby grants to Sunesis a worldwide, exclusive license under DOT-1’s interest in
the DOT-1 Collaboration Technology, Joint Collaboration Technology, Development Technology and other Patent Rights and Know How in existence and owned by DOT-1 as of the
date the relevant Licensed Product becomes a Reverted Licensed Product (“Other DOT-1 Technology”), with the right to grant and authorize sublicenses as provided in Section 5.2, to
develop, make, have made, use, import, offer for sale, sell and otherwise exploit such Reverted Licensed Product in the Field (the “Sunesis Reversion License”). It is understood and acknowledged that the licenses granted with
respect to DOT-1 Collaboration Technology, Development Technology and Other DOT-1 Technology in this Section 5.1.3 extend solely to that technology that is being
used by or on behalf of DOT-1 or its Affiliate or Sublicensee in the development or commercialization of that Reverted Licensed Product as of the date of such reversion to Sunesis, and solely to the extent
necessary for Sunesis to continue development and commercialization of such Reverted Licensed Product in the form in which such Reverted Licensed Product existed as of the date of such reversion to Sunesis. For purposes of the Sunesis Reversion
License, the Field shall exclude the prevention, diagnosis and treatment of Cardiofaciocutaneous Syndrome, giant congenital melanocytic nervus, Noonan Syndrome, and Noonan Syndrome with multiple lentigines, solely in the event that the Sunesis
Reversion License goes into effect without a prior Millennium Reversion and solely to the extent that Millennium retains right to such indications as of the date that the Sunesis Reversion License become effective. 

5.2 Grant of Sublicenses. Within a reasonable period of time following grant of any sublicense, to the extent sublicensing is permitted
under Section 5.1, the sublicensing Party shall provide the other Party with a summary of such sublicense, including the identity of the Sublicensee (including any Affiliate) and the rights granted with respect thereto for each product and
territory, sufficient to allow such other Party to verify any amounts then or subsequently due under Article 6 below; provided that such summary may redact confidential information that the sublicensing Party is reasonably prohibited from disclosing
under the sublicense agreement. Any sublicense granted under this Section 5.2 shall be consistent with all of the terms and conditions of this Agreement, and subordinate thereto, and the sublicensing Party shall remain responsible to the other
Party for the compliance of each such Sublicensee with the obligations due under this Agreement. 
 5.3 Covenants with Respect to
Compounds in the Field. 
 5.3.1 Sunesis Covenant for Raf Target. During the Term of this Agreement, Sunesis represents, warrants
and agrees that it shall not, alone or through any Third Party, and shall ensure that its Affiliates do not, market, sell or promote any pharmaceutical compound that is 

  
 10 

 
Target Selective against the Raf Target, other than as permitted under Section 8.2 and Section 15.3 (provided that Sunesis complies with the obligations in such Section 15.3).
Notwithstanding the foregoing, Sunesis shall not be prohibited from collaborating with a Third Party on the development and commercialization of chemical compounds in-licensed from or controlled by such Third
Party against the Raf Target. 
 5.4 No Other Rights; No Implied Licenses. Only the licenses granted or retained pursuant to the
express terms of this Agreement shall be of any legal force or effect. No other license rights shall be created by implication, estoppel or otherwise. 

ARTICLE 6 
 PAYMENTS

 6.1 Upfront Fee. DOT-1 shall pay to Sunesis the following amounts within thirty
(30) days following the Effective Date: $2,000,000. 
 6.2 Development Milestones. 

6.2.1 Development Milestone Payments. 

(a) DOT-1 will pay Sunesis [*]. 

(b) With respect to each Licensed Product, DOT-1 shall pay to Sunesis on a Licensed Product-by-Licensed Product basis the following amounts within [*] following the first achievement by DOT-1, its Affiliates or
Sublicensees, as the case may be, of each of the following milestones with respect to such Licensed Product: 
  

									
	 	  	Payment Amount	 
	 Development Milestones
	  	1st Indication	 	 	2nd Indication	 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 
	 [*]
	  	 	[	*] 	 	 	[	*] 

 Such milestone payments shall be non-refundable and non-creditable against other amounts due Sunesis hereunder. [*]. 

  
 11 

 6.2.2 Certain Additional Terms. 

(a) Licensed Product-by-Licensed Product Milestones. It
is understood that, subject to Section 6.2.2(b), the payments under this Section 6.2 shall be due only once with respect to each Licensed Product; provided that the payments under Section 6.2.1(a) shall be due only with respect to
consideration for the first sale of each PRV received by DOT-1 or its Affiliate or Sublicensee. 

(b) Multiple Indications. With respect to a particular Licensed Product, if such Licensed Product is developed for a second Indication
in a separate disease, it is understood that the payments for the Development Milestones set forth in Section 6.2.1(b) will become due and payable at the time such Licensed Product achieves such Development Milestone for such second Indication;
provided, that the amounts due above for such second Indication will be the lower amounts reflected for such Indications in the right most column of the table under Section 6.2.1(b) above. As used herein “Indication” shall mean
a disease or condition for which approval for use of a Licensed Product can be sought from the FDA or a regulatory authority or agency of a country other than the United States with responsibilities comparable to those of the FDA. Notwithstanding
the foregoing, varying forms or degrees of severity of the same disease shall be considered the same Indication, even if they require separate approvals from the FDA or other regulatory authority or agency. For the avoidance of doubt, in the field
of cancer, different tumor tissue types shall be considered different Indications. 
 (c) Discontinued Licensed Products. If DOT-1 ceases all clinical development of a particular Licensed Product, after having made one or more of the payments due under Section 6.2.1(b) above on the achievement of a particular milestone by such
Licensed Product, there shall be no payment due upon the accomplishment of that same milestone with respect to the next Licensed Product to achieve such milestone. 

(d) Accrued Milestones. If any of the development milestones 2-7 for a Licensed Product under
Section 6.2.1(b) above is achieved with respect to such Licensed Product before development milestone 1 under Section 6.2.1(b) for such Licensed Product, then the milestone payment associated with development milestone 1 shall then also be
due with respect to such Licensed Product upon the first achievement of any of milestones 2-7. Additionally, if any of the development milestones 5-7 for a Licensed
Product is achieved with respect to such Licensed Product before the corresponding development milestone 2-4 for such Licensed Product in the same territory (meaning, as applicable, the U.S., EMEA, or Japan),
then the applicable milestone payment associated with that development milestone 2-4 for that territory shall also be due with respect to such Licensed Product upon the achievement of such development
milestone 5-7. 
 6.2.3 Reports; Payments. Within [*] of the occurrence of any event which
would trigger a milestone payment according to Section 6.2.1(b), DOT-1 shall inform Sunesis of such occurrence. The corresponding payment shall be due [*] after the occurrence of such event. 

  
 12 

 6.3 Royalties on Annual Net Sales of Licensed Products. 

6.3.1 Licensed Products Generally. Subject to Sections 6.3.3 and 6.3.4, DOT-1 shall pay to
Sunesis a royalty on Net Sales by DOT-1, its Affiliates and their Sublicensees of Licensed Products on a Licensed
Product-by-Licensed Product basis, equal to the percentage of such Net Sales set forth below: 
  

			
	 Annual Net Sales
	  	Royalty on Net Sales
	 Portion of Annual Net Sales of such Licensed Product up to [*]:
	  	[*]
	 Portion of Annual Net Sales of such Licensed Product over [*]:
	  	[*]

 For purposes of the foregoing, “Annual Net Sales” shall mean, for a particular Licensed
Product, the worldwide Net Sales of such Licensed Product for the particular calendar year. 
 6.3.2 Reserved. 

6.3.3 Third Party Patents. 
 (a)
If: (i) a Valid Claim of a Third Party should be in force in any country during the Term of this Agreement covering the practice of the Sunesis Licensed Technology as licensed to DOT-1 under
Section 5.1 with respect to the manufacture, use or sale of any Licensed Product, (ii) it should prove in DOT-1’s reasonable judgment, after consultation with Sunesis, impractical or impossible
for DOT-1 to commercialize such Licensed Product without obtaining a royalty bearing license from such Third Party under such Valid Claim in said country (with such agreement not to be unreasonably withheld or
delayed), and (iii) the royalty paid to such Third Party is directed to the practice of rights granted to DOT-1 under Section 5.1 with respect to such Licensed Product, then DOT-1 shall be entitled to a credit against the royalty payments due under the other provisions of this Section 6.3 with respect to the same Licensed Product in such country of an amount equal to [*] of the
royalty paid to such Third Party for such Licensed Product in such country, arising from the practice of such Sunesis Licensed Technology with respect to the manufacture, use or sale of the Licensed Product in said country, with such credit not to
exceed [*] of the royalty otherwise due under this Agreement for such Licensed Product in such country. 
 (b) If: (i) a Valid Claim
of a Third Party should be in force in any country during the Term of this Agreement covering the practice of the DOT-1 Collaboration Technology, Joint Collaboration Technology, Development Technology or Other
DOT-1 Technology licensed to Sunesis under Section 5.1.3, in each case with respect to the manufacture, use or sale of any Reverted Licensed Product, (ii) it should prove in Sunesis’s reasonable
judgment, after consultation with Millennium, impractical or impossible for Sunesis to commercialize such Reverted Licensed Product without obtaining a royalty bearing license from such Third Party under such Valid Claim in said country (with such
agreement not to be unreasonably withheld or delayed), and (iii) the royalty paid to such Third Party is directed to the practice of rights granted to Sunesis under Section 5.1.3 with respect to such Reverted Licensed Product, then Sunesis
shall be entitled to a credit against the royalty payments due under Section 6.4 with respect to the same Reverted Licensed Product in such country of an amount equal to [*] of the royalty paid to such Third Party for such Reverted Licensed
Product in such country, arising from the practice of the intellectual property described above with respect to the manufacture, use or sale of the Reverted Licensed Product in said country, with such credit not to exceed [*] of the royalty
otherwise due under this Agreement for such Reverted Licensed Product in such country. 

  
 13 

 6.3.4 Royalty Reduction. The royalty rates set forth in Sections 6.3.1 used to
calculate royalties payable on Net Sales of a Licensed Product in a country shall be reduced by [*] during any portion of the applicable period under Section 6.5 in which (a) no Valid Claim of the Sunesis Licensed Patents Covers the sale
or use of such Licensed Product in such country and (b) such Licensed Product is not protected under any statutory exclusivity granted by a Governmental Authority (“Statutory Exclusivity”) in such country, including orphan drug
exclusivity granted by the FDA. 
 6.4 Royalties on Net Sales of Reverted Licensed Products. Sunesis shall pay DOT-1 royalties, at a royalty rate equal to the royalty rate provided under Section 6.3.1, with respect to Net Sales of Reverted Licensed Products by Sunesis, its Affiliates and their Sublicensees; provided,
however, that such royalty rate shall be reduced by [*] with during any portion of the applicable period under clause (ii) in Section 6.5.1 in which (a) no Valid Claim of the DOT-1 Collaboration
Patents, Joint Collaboration Patents, Development Technology or Other DOT-1 Technology Covers the sale or use of such Reverted Licensed Product in such country and (b) such Reverted Licensed Product is
not protected under any Statutory Exclusivity in such country. 
 6.5 Royalty Term. 

6.5.1 The royalties due pursuant to Section 6.3 and Section 6.4 above shall be payable on a country-by-country and Product-by-Product basis commencing on the first commercial sale in a country and continuing until the
later of: (i) the expiration of the last Valid Claim of (a) the Sunesis Licensed Patents Covering the sale or use of the relevant Licensed Product in such country or (b) the Joint Collaboration Patents,
DOT-1 Collaboration Patents, Development Technology or Other DOT-1 Technology Covering the sale or use of the relevant Reverted Licensed Product in such country,
(ii) the expiration of the last Statutory Exclusivity pertaining to such Product in such country or (iii) the tenth (10th) anniversary of the first commercial sale of such Product in
such country. 
 6.5.2 DOT-1 acknowledges that it will continue to benefit from its license under,
and the transfer to DOT-1 of certain elements of, the Sunesis Licensed Technology, and DOT-1’s own development of Know-How
derived from the practice of such Sunesis licenses and DOT-1’s use of such Sunesis Licensed Technology, even after the expiration of all Patent Rights that claim a Licensed Product in a particular
country. Sunesis acknowledges that it will continue to benefit from its license under certain elements of, the DOT-1 Collaboration Technology, Joint Collaboration Technology, Development Technology and Other DOT-1 Technology, and Sunesis’ own development of Know-How derived from the practice of such licenses and Sunesis’ use of such licensed technology, even after the
expiration of all Patent Rights that claim a Reverted Licensed Product in a particular country. The Parties acknowledge that such structure is more convenient to the Parties, facilitates the payment of compensation between the Parties for access to
Know How and reduces accounting burdens on the Parties. Accordingly, the Parties have agreed to apply the royalty structure as provided in this Article 6. 

  
 14 

 ARTICLE 7 

PAYMENTS, BOOKS AND RECORDS 

7.1 Royalty Reports and Payments. After the first sale of a Product on which royalties are payable by a Party hereunder, such Party
shall make quarterly written reports to the other Party within [*] after the end of each calendar quarter, stating in each such report, separately the number, description, and aggregate Net Sales, by territory, of each such Product sold during the
calendar quarter upon which a royalty is payable under Section 6.3 or Section 6.4 above, as applicable. Concurrently with the making of such reports, such Party shall pay to the other Party royalties due at the rates specified in
Section 6.3 or Section 6.4 above, as applicable. 
 7.2 Payment Method. All payments due under this Agreement shall be made
by bank wire transfer in immediately available funds to a bank account designated by the Party owed such payment. All payments hereunder shall be made in U.S. dollars. Any payments that are not paid on the date such payments are due under this
Agreement shall bear interest to the extent permitted by applicable law at a rate equal to the 3-month LIBOR rate at the close of business on the date such payment is due, plus an additional [*], calculated on
the number of days such payment is delinquent. 
 7.3 Place of Royalty Payment; Currency Conversion. The functional currency for
accounting will be U.S. dollars. Except as the Parties otherwise mutually agree, for billing and reporting, Net Sales will be translated, if necessary, into U.S. dollars using the currency exchange rates quoted by Bloomberg Professional, a
service of Bloomberg L.P., or in the event Bloomberg Professional is not available, then the Eastern U.S. edition of The Wall Street Journal on the last business day of the applicable calendar quarter. 

7.4 Records; Inspection. Each Party shall keep, and shall ensure that its Affiliates keep, complete, true and accurate books of account
and records for the purpose of determining the amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of such Party, for at least [*] following the end of the calendar quarter to which they
pertain. Such records will be open for inspection by a public accounting firm to whom the audited Party has no reasonable objection and subject to such accounting firm entering into a satisfactory confidentiality agreement, solely for the purpose of
determining the payments to the other Party hereunder. Such inspections may be made no more than twice each calendar year, at reasonable times and on reasonable notice. Inspections conducted under this Section 7.4 shall be at the expense of the
auditing Party, unless a variation or error producing an increase exceeding [*] of the amount stated for the period covered by the inspection is established in the course of any such inspection, whereupon all reasonable costs relating to the
inspection for such period and any unpaid or overpaid amounts that are discovered will be promptly paid or refunded by the appropriate Party, in each case together with interest noted in Section 7.2 thereon from the date such payments were due
(if underpaid) or paid (if overpaid). 
 7.5 Withholding Taxes. Each Party shall pay any and all taxes levied on account of amounts
payable to it under this Agreement. If laws or regulations require that taxes be withheld, the paying Party will (i) deduct those taxes from the remittable payment, (ii) timely pay the taxes to the proper authority, and (iii) send
proof of payment to the other Party within [*] following that payment. 

  
 15 

 ARTICLE 8 

DILIGENCE 
 8.1
Diligence; Reports. DOT-1 agrees to keep Sunesis fully informed regarding the Development and commercialization activities with respect to each Licensed Product by providing reports to Sunesis at least
quarterly regarding ongoing activities being undertaken with respect to Licensed Products. In addition, DOT-1 shall provide Diligence Summaries to Sunesis with respect to each Licensed Product on a semi-annual
basis during the Term of this Agreement. This Section 8.1 shall not limit other provisions of this Agreement that address the provision of information regarding Licensed Products. 

8.2 Reversion of a Licensed Product. 

8.2.1 After Millennium Reversion. If, in each case after a Millennium Reversion, a Diligence Failure occurs, or Sunesis
terminates this Agreement pursuant to Section 13.2 for DOT-1’s breach or pursuant to Section 13.3 for DOT-1’s bankruptcy, or DOT-1 terminates this Agreement pursuant to Section 13.4 for convenience with respect to a Licensed Product, Sunesis shall have the right to assume the development and commercialization of such Licensed
Product, subject to the terms and conditions of this Agreement, including Section 5.1.2 and this Section 8.2, upon written notice to DOT-1. Upon the effective date of such notice from Sunesis,
subject to Section 5.1.2, such Licensed Product shall be designated a “Reverted Licensed Product”, the terms set forth in Section 1 of Exhibit 8.2 attached hereto shall thereafter apply, and Sunesis shall pay royalties to DOT- 1 as provided under Section 6.4 on Net Sales of such Reverted Licensed Product by Sunesis, its Affiliates or Sublicensees. For purposes of this Section 8.2, a “Diligence Failure”
means if DOT-1 or, after a Millennium Reversion with respect to a Licensed Product that includes an assignment of this Agreement to Millennium, Millennium fails to use Commercially Reasonable and Diligent
Efforts to Develop, obtain Regulatory Approvals and necessary pricing or reimbursement approvals (if any) for and commercialize a Licensed Product in the Field, and DOT-1 or Millennium, as applicable, shall
continue to fail to use such Commercially Reasonable and Diligent Efforts to develop and commercialize such Licensed Product for [*] after written notice thereof from Sunesis. 

8.2.2 Prior to a Millennium Reversion. If, prior to a Millennium Reversion, (a) a Diligence Failure occurs,
(b) Sunesis notifies DOT-1 in writing that Sunesis intends to terminate this Agreement pursuant to Section 13.2 for DOT-1’s breach or pursuant to
Section 13.3 for DOT-1’s bankruptcy or (c) DOT-1 notifies Sunesis in writing that DOT- 1 intends terminate this
Agreement pursuant to Section 13.4 for convenience with respect to a Licensed Product, then Sunesis shall promptly notify Millennium in writing (with a copy to DOT-1) and offer Millennium the option to
receive an assignment from DOT-1 of all of DOT-1’s rights and obligations under this Agreement (as part of a Millennium Reversion) or to waive its right to a
Millennium Reversion (such notice, the “Option Notice” and such option, the “Millennium Option”). If Millennium exercises the Millennium Option, in its discretion, by written notice to Sunesis (with a copy to DOT-1) within [*] after the date of the Option Notice (such period, the “Millennium Option Period”) to receive an assignment of this Agreement, then, upon timely receipt of

  
 16 

 
Millennium’s exercise notice, (i) DOT-1 shall assign this Agreement, including all of DOT-1’s rights
and obligations thereunder, to Millennium, (ii) Millennium shall assume all such obligations in writing to Sunesis, (iii) all references to DOT-1 in this Agreement shall, with respect to events and
activities after such assignment, be deemed to be references to Millennium, (iv) this Agreement will remain in full force and effect, and (v) Sunesis will not have the right to assume the development and commercialization of such Licensed
Product and such Licensed Product shall not become a Reverted Licensed Product, in the case of (iv) and (v) unless and until (a), (b) or (c) above happens another time after a Millennium Reversion, in which case Section 8.2(a) shall
apply. If Millennium exercises the Millennium Option to waive its rights to the Millennium Reversion before the end of the Millennium Option Period, then the termination pursuant to Section 13.2, 13.3 or 13.4 (as applicable) shall become
effective upon the later of (x) the date such termination is specified in such Section to take effect or (y) the end of the Millennium Option Period, and such Licensed Product shall be designated a “Reverted Licensed Product”,
the terms set forth in Section 1 of Exhibit 8.2 attached hereto shall thereafter apply, and Sunesis shall pay royalties to DOT-1 as provided under Section 6.4 on Net Sales of such Reverted Licensed
Product by Sunesis, its Affiliates or Sublicensees. If Millennium does not exercise the Millennium Option during the Millennium Option Period, then Sunesis may terminate this Agreement pursuant to Section 13.2 for
DOT-1’s breach or pursuant to Section 13.3 for DOT-1’s bankruptcy, but no Licensed Product shall become a Reverted Licensed Product and the licenses set
forth in Section 5.1.3 shall not apply. 
 8.3 Diligence for a Reverted Licensed Product. Sunesis shall use Commercially
Reasonable and Diligent Efforts to develop and commercialize each Reverted Licensed Product. Sunesis agrees to keep DOT-1 fully informed regarding the development and commercialization activities with respect
to each Reverted Licensed Product, including by providing DOT-1 with reports at least quarterly regarding ongoing activities being undertaken with respect to Reverted Licensed Products. In addition, Sunesis
shall provide DOT-1 with a Diligence Summary with respect to each Reverted Licensed Product on a semi-annual basis during the Term of this Agreement. 

8.4 Termination of a Reverted Licensed Product. If Sunesis fails to use Commercially Reasonable and Diligent Efforts to develop and
commercialize a Reverted Licensed Product, and Sunesis shall continue to fail to use Commercially Reasonable and Diligent Efforts to develop and commercialize such Reverted Licensed Product for [*] after written notice thereof from DOT-1, then such Reverted Licensed Product shall cease to be a Reverted Licensed Product, and the license granted to Sunesis under Section 5.1.3 shall terminate with respect to such Reverted Licensed Product.
Thereafter, such Reverted Licensed Product shall be a Licensed Product and subject to DOT-1’s licenses under Section 5.1 and obligations to pay royalties and milestones to Sunesis pursuant to Article
6. In addition, the terms set forth in Section 2 of Exhibit 8.2 shall apply to such Reverted Licensed Product. 
 8.5 Disputes.
In the event that there is a good faith dispute as to whether the activities described in a Diligence Summary constitute Commercially Reasonable and Diligent Efforts to develop and commercialize the applicable Licensed Product or Reverted Licensed
Product, then either Party may refer the dispute to a senior executive from each Party. Such senior executive 

  
 17 

 
shall be either the CEO or President of such Party, or other senior executive of such Party with the title of Vice President or higher and who has direct management responsibility for the matter
in dispute. Upon such request, such senior executives shall make themselves reasonably available to meet, and shall meet either by telephone or if, specifically requested, in person, to attempt to resolve such matter, and shall thereafter continue
to use good faith efforts to attempt to resolve such matter unless it becomes clear that the matter cannot be resolved by mutual agreement. Thereafter either Party may pursue such legal process as is otherwise available under applicable law. 

ARTICLE 9 
 INTELLECTUAL
PROPERTY 
 9.1 Ownership; Disclosure. 

9.1.1 Collaboration Technology. 

(a) Raf Technology. All right, title, and interest in and to the Joint Collaboration Patents, the subject of which are inventions that
were developed in the course of activities that were directed to the Raf Target or to the discovery, research, or development of Licensed Compounds which are Target Selective to the Raf Target or Licensed Products incorporating such Licensed
Compounds, are jointly owned by DOT-1 and Sunesis, as is all other Joint Collaboration Technology. Except as expressly provided in this Agreement, neither Party shall have any obligation to account to the
other for profits, or to obtain any approval of the other Party to assign, license, exploit or enforce the Joint Collaboration Technology, by reason of joint ownership thereof, and each Party hereby waives any right it may have under the laws of any
jurisdiction to require any accounting or consent related thereto. It is understood and agreed that Sunesis and its Affiliates’ interest in all Joint Collaboration Technology shall be subject to the licenses granted under Article 5. 

(b) Sunesis Collaboration Technology. Subject to Section 9.1.1(a), all right, title, and interest in and to the Sunesis
Collaboration Technology shall be owned by Sunesis, subject to the licenses granted to DOT-1 under Article 5. 

(c) Reserved. 
 (d) Reserved.

 9.1.2 Development Technology. All right, title and interest in and to the Development Technology and the DOT-1 Collaboration Technology shall, as between the Parties, be owned solely by DOT-1. 

9.2 Patent Prosecution. 

9.2.1 Reserved. 
 9.2.2
Collaboration Patents and Development Patents. DOT-1 shall have the first right, using in-house or outside legal counsel selected by DOT-1, subject to approval, not to be unreasonably withheld, by Sunesis, to prepare, file, prosecute, maintain, and obtain extensions 

  
 18 

 
throughout the world of the Sunesis Licensed Patents, the Collaboration Patents, and Patent Rights in the Development Technology that claim or cover the Raf Target, Licensed Compounds or Licensed
Products, or the use of manufacture thereof. DOT-1 shall: (a) ensure that Sunesis receives copies of all correspondence between DOT-1 or outside legal counsel or
any governmental offices relating to such preparation, filing, prosecution, maintenance, and obtaining of extensions, of such Sunesis Licensed Patents, Sunesis Collaboration Patents, Joint Collaboration Patents and other Patent Rights subject to
this Section 9.2.2 (“Other Patent Rights”), (b) timely consult with Sunesis regarding all substantive matters associated with such activities in (a), (c) use reasonable efforts to periodically advise Sunesis on such activities
and to respond to any reasonable inquiries Sunesis may from time to time raise in respect of such activities in (a) or (b), and (d) not substantially negatively impact Sunesis’s rights under such Sunesis Licensed Patents or
Collaboration Patents. As used in this Article 9, “prosecution” shall include interferences, re-examinations, reissues, oppositions and the like. 

9.2.3 Prosecution Costs. All costs incurred by DOT-1 after the Effective Date associated with
filing, prosecuting, issuing, maintaining, and extending the Patent Rights described in Section 9.2.2 shall, as between the Parties, be borne by DOT-1. 

9.2.4 Cooperation. Each Party will cooperate fully with the other Party and provide all information and data, and sign any documents,
reasonably necessary and requested by the other Party for the purpose of preparing, filing and prosecuting patent applications pursuant to this Section 9.2. 

9.2.5 Abandonment. 

(a) DOT-1 may elect to decline to file or, having filed, decline to further prosecute
and maintain any Sunesis Licensed Patent, Sunesis Collaboration Patent, Joint Collaboration Patent or Other Patent Rights, in which event DOT-1 shall provide Sunesis with written notice thereof prior to the
expiration of any deadline, without considering any possible extensions thereof, relating to such activities, but in any event at least [*] prior notice. In such circumstances Sunesis shall have the right to decide, with reason and with written
notice at least [*] prior to the deadline, that DOT-1 should continue to file or prosecute such Patent Right. DOT-1 shall then have the option to decide, with at least
[*] notice to Sunesis to: (i) continue to file or prosecute such Patent Right at its cost and expense, or (ii) allow Sunesis to file or prosecute such Patent Right at its own cost and expense using counsel of its own choice. In the event
that DOT-1 elects option (ii), then DOT-1 shall cooperate with Sunesis to promptly transfer relevant prosecution materials to Sunesis. 

(b) It is understood and agreed that transfer of prosecution of particular Patent Rights pursuant to subsection (ii) in
Section 9.2.5(a) above shall not affect the ownership or licenses otherwise provided in this Agreement. 
 9.3 Enforcement. 

9.3.1 Notice. In the event a Party becomes aware of any actual or potential infringement or misappropriation of (a) the Sunesis
Licensed Technology, Joint Collaboration 

  
 19 

 
Technology, DOT-1 Collaboration Technology or Sunesis Collaboration Technology in each case that relates to the Raf Target or Licensed Compounds or
Licensed Products or (b) the Joint Collaboration Technology ((a) and (b), each, a “Subject Infringement”), such Party shall notify the other Party. 

9.3.2 DOT-1. DOT-1 shall have the sole right, but not
the obligation, to take legal action to: 
 (a) enforce and defend the Sunesis Licensed Technology or the Sunesis
Collaboration Technology against Subject Infringements by Third Parties at its sole cost and expense. If, within [*] following a request by Sunesis to do so, DOT-1 fails to use commercially reasonable efforts
to take such action to enforce and defend any actual or potential infringement or misappropriation of the Sunesis Licensed Technology or Sunesis Collaboration Technology with respect to a Subject Infringement, Sunesis or its designee shall, in its
sole discretion, have the right, at its sole expense, to take such action. 
 (b) enforce and defend the DOT-1 Collaboration Technology or Joint Collaboration Technology against Subject Infringements by Third Parties at its sole cost and expense. If, within [*] following a request by Sunesis to do so, DOT-1 (either directly or indirectly through Millennium or a Sublicensee) fails to use commercially reasonable efforts to take such action to enforce and defend any actual or potential infringement or
misappropriation of the DOT-1 Collaboration Technology or Joint Collaboration Technology against a Subject Infringement, Sunesis or its designee shall, in its sole discretion, have the right, at its sole
expense, to take such action; provided that Millennium has not commenced action to enforce or defend any infringement or misappropriation of the DOT-1 Collaboration Technology or Joint Collaboration
Technology. 
 9.3.3 Sunesis. To the extent an infringement or misappropriation of the Sunesis Licensed Technology or Sunesis
Collaboration Technology is not a Subject Infringement covered by Section 9.3.2 above, Sunesis (or its designee) shall have the initial right, but not the obligation, to take reasonable legal action to enforce and defend the Sunesis Licensed
Technology or Sunesis Collaboration Technology against such infringement or misappropriation by Third Parties at its sole cost and expense. If, within [*] following a request by DOT-1 to do so, Sunesis (or its
designee) fails to take such action to enforce and defend any actual or potential infringement or misappropriation of the Sunesis Licensed Technology or Sunesis Collaboration Technology with respect to such Subject Infringement, DOT-1 or its designee shall, in its sole discretion, have the right, at its sole expense, to take such action. 

9.3.4 Cooperation. If a Party (the “Controlling Party”) brings an action in accordance with this Section 9.3 (an
“Infringement Action”), then the other Party (the “Cooperating Party”) shall cooperate as reasonably requested, at such Controlling Party’s expense, in the pursuit of such Infringement Action, including
if necessary by joining as a nominal Party to the Infringement Action. In any case, the Cooperating Party shall have the right, even if not required to be joined, to participate in such Infringement Action with its own counsel at its own expense.
The costs and expenses of the Infringement Action shall be the responsibility of the Controlling Party, and any damages or other monetary rewards or settlement payments actually received and retained by the Controlling Party shall first be applied
to reimburse the Controlling 

  
 20 

 
Party’s out-of- pocket expenses directly attributed to the Infringement Action, then the other Party’s out-of-pocket expenses directly attributed to the Infringement Action, then the other Party’s
out-of-pocket expenses directly attributed to the Infringement Action, and the remainder shall be shared as follows: [*]. 

ARTICLE 10 

CONFIDENTIALITY 
 10.1
Confidentiality. During the Term of this Agreement and for a period of [*] following the expiration or earlier termination hereof, each Party shall maintain in confidence the Confidential Information of the other Party, shall not use or grant
the use of the Confidential Information of the other Party except as expressly permitted hereby, and shall not disclose the Confidential Information of the other Party (in each case, irrespective of whether such Confidential Information is also the
Confidential Information of the receiving Party), except (i) on a need-to-know basis to such Party’s directors, officers and employees, (ii) to such
Party’s consultants performing work contemplated by the Agreement, and to any bona fide subcontractor performing work for such Party hereunder, or (iii) to the extent such disclosure is reasonably necessary in connection with such
Party’s activities under rights and licenses expressly authorized by this Agreement (including the permitted sublicensees). To the extent that disclosure to any person is authorized by this Agreement, prior to disclosure, a Party shall obtain
written agreement of such person to hold in confidence and not disclose, use or grant the use of the Confidential Information of the other Party except as expressly permitted under this Agreement. Each Party shall notify the other Party promptly
upon discovery of any unauthorized use or disclosure of the other Party’s Confidential Information. 
 10.2 Permitted Use and
Disclosures. The confidentiality obligations under this Article 10 shall not apply to the extent that a Party is required to disclose information by applicable law, regulation or order of a governmental agency or a court of competent
jurisdiction; provided, however, that such Party shall provide written notice thereof to the other Party (to the extent not prohibited by law or court order), and consult with the other Party with respect to such disclosure to the
extent reasonably protectable and provide the other party reasonable opportunity to object to any such disclosure or to request confidential treatment thereof. Notwithstanding the provisions of this Section, either Party may, to the extent
necessary, disclose Confidential Information of the other Party, to any governmental or regulatory authority in connection with the development of a product which it has the right to develop under this Agreement. 

10.3 Nondisclosure of Terms. Each of the Parties hereto agrees not to disclose the financial terms of this Agreement to any Third Party
without the prior written consent of the other Party hereto, which consent shall not be unreasonably withheld, except (a) to such Party’s attorneys, advisors, investors, potential bona fide collaborators and Sublicensees, and others
on a need-to-know basis under circumstances that reasonably protect the confidentiality thereof; (b) or to the extent required by law (and with appropriate requests
made for confidential treatment), including filings required to made by law with the Securities and Exchange Commission or any national securities exchange; provided, however, that, with respect to any filing required to made by law with the
Securities and Exchange Commission or any national securities exchange, the Party subject to such filing requirement shall, at least [*] in advance of any such filing, provide the other Party with a draft set of redactions to this Agreement for
which confidential treatment 

  
 21 

 
will be sought, reasonably incorporate the other Party’s comments as to additional terms it would like to see redacted, and seek confidential treatment for such additional terms (except only
in the limited circumstances where confidential treatment is in the opinion of outside counsel unavailable); or (c) to Millennium, to the extent required in connection with a Millennium Reversion and under circumstances that reasonably protect
the confidentiality thereof. Notwithstanding the foregoing, (i) Sunesis may issue any press release to be mutually agreed by the Parties, and (ii) each Party may disclose the information contained in such press release (and related
Securities and Exchange Commission filing) without the consent of the other Party. 
 10.4 Publication. 

10.4.1 For clarity, nothing in this Section 10.4 shall be deemed to limit the publication or disclosure right of Sunesis with respect to a
Reverted Licensed Product; provided that Sunesis shall provide DOT-1 with a courtesy copy of such manuscript prior to its publication. 

10.4.2 By DOT-1. As between the Parties, DOT-1 shall
have the sole right, but not the obligation, to publish or publicly disclose, in its sole discretion, any manuscript containing scientific or clinical results with respect to Licensed Products generated during the Term or included in the
Collaboration Technology, in each case as relating to the Raf Target, Licensed Compounds or Licensed Products, and shall provide Sunesis with a courtesy copy of such manuscript prior to its publication. 

10.4.3 Reserved. 
 ARTICLE 11

 REPRESENTATIONS AND WARRANTIES 

11.1 Warranty. Each Party represents and warrants on its own behalf and on behalf of its Affiliates that as of the Effective Date: 

(i) Such Party is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized. 

(ii) It has the legal power and authority to enter into this Agreement and to perform all of its obligations hereunder. 

(iii) This Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms. 

(iv) All necessary consents, approvals and authorizations of all governmental authorities and other persons or entities required to be
obtained by such Party in connection with this Agreement have been obtained. 
 (v) The execution and delivery of this Agreement and the
performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable laws, regulations or orders of governmental bodies; and (b) do not conflict with, or constitute a default under, any
contractual obligation of such Party. Neither Party will enter into any agreement with any Third Party that conflicts with the terms of this Agreement. 

  
 22 

 (vi) Such Party requires, and shall require, that all of its employees and consultants
involved in the Development, manufacture or commercialization of Licensed Compounds, Licensed Products, Reverted Compounds or Reverted Licensed Products have entered into written agreements obligating such person to assign any rights s/he may have
in any inventions made during such work to such Party. 
 11.2 Additional Warranties of Sunesis. Sunesis represents and warrants to DOT-1 as of the Effective Date that: 
 11.2.1 Sunesis has not received any notice of
infringement or misappropriation from any Third Party relating to the Sunesis Licensed Technology; 
 11.2.2 Sunesis has not
received any notice challenging the scope of validity of the Sunesis Licensed Technology; 
 11.2.3 To Sunesis’
knowledge, the Sunesis Licensed Technology is legally possessed by Sunesis and has not been misappropriated from any Third Party; 

11.2.4 To Sunesis’ knowledge, the Patent Rights listed on Exhibits 1.18, 1.37, and 1.38 comprise all Patent Rights
Controlled by Sunesis or its Affiliates as of the Effective Date that claim or cover the Raf Target, the Licensed Compounds and Licensed Products; 

11.2.5 Sunesis has the right to grant the licenses set forth herein under the Patent Rights set forth on Exhibits 1.37, 1.38,
and 1.18; 
 11.2.6 Sunesis has not granted any rights that conflict with those granted to
DOT-1 pursuant to this Agreement; 
 11.2.7 To the extent that there are still any
pending Patent Rights (i.e. all Patent Rights except those that have expired or been abandoned) included in the definition of Sunesis Core Technology (as such term is defined in the Raf Agreement), to Sunesis’ knowledge, Sunesis is not aware of
any such Patent Rights that cover the composition of matter of the Licensed Compounds, or their manufacture or use for any indication. 

11.3 Additional Warranties of DOT-1. DOT-1 represents
and warrants to Sunesis as of the Effective Date that: 
 11.3.1 the Patent Rights and
Know-How on Exhibits 1.14 and 1.18 comprise all of the Patent Rights and Know-How to which DOT-1 received rights from Millennium
pursuant to the ATLA and related documents entered into between DOT-1 and Millennium in connection therewith (collectively, the “Transaction Documents”); 

11.3.2 DOT-1 has the right to grant has the right to grant the licenses set forth
herein under such Patent Rights and Know-How; and 
 11.3.3 the document entitled
“ 20191212 Takeda Agreement – Reversion Terms Document.docx” that was provided by DOT-1’s counsel to Sunesis’ counsel on December 12, 2019 is a complete and accurate copy of the
identified provisions and definitions of the ATLA and it completely and accurately describes all of the effects of termination of the ALTA with respect to the Millennium Reversion. 

  
 23 

 11.4 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER
PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE COLLABORATION TECHNOLOGY, DEVELOPMENT TECHNOLOGY, OTHER DOT-1 TECHNOLOGY, LICENSED COMPOUNDS, OTHER
COMPOUNDS, LICENSED PRODUCTS, RAF TARGET OR CONFIDENTIAL INFORMATION, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF ANY COLLABORATION TECHNOLOGY, PATENTED OR UNPATENTED, OR NONINFRINGEMENT OF THE INTELLECTUAL
PROPERTY RIGHTS OF THIRD PARTIES. 
 ARTICLE 12 

INDEMNIFICATION 
 12.1 DOT-1. DOT-1 shall indemnify, defend and hold harmless Sunesis and its Affiliates and their respective directors, officers, employees, agents and their respective
successors, heirs and assigns from and against any losses, costs, claims, damages, liabilities or expense (including reasonable attorneys’ and professional fees and other expenses of litigation) (collectively, “Liabilities”)
resulting from any claims, demands, actions or other proceedings by any Third Party to the extent resulting from: (i) the manufacture, use, sale, handling or storage of Licensed Products by (a) Millennium or its Affiliates or Sublicensees
(as defined in the Prior License Agreement) or other designees or (b) DOT-1 or its Affiliates or Sublicensees or other designees (except in each case with respect to claims of infringement or violation of
intellectual property rights, which shall be governed solely by clause (iv)); (ii) the breach by DOT-1 of the representations and warranties made in this Agreement; (iii) the negligence or intentional
misconduct of DOT-1 or any of its agents or employees or failure of DOT-1 or any of its agents or employees to comply with applicable laws and regulations; or
(iv) a claim that the use, manufacture, sale or importation of a Licensed Product infringes or violates the intellectual property rights of a Third Party (other than if such infringement or violation results solely from the practice of any
Sunesis Licensed Technology (excluding any Joint Collaboration Patents and Joint Collaboration Know-How) in accordance with this Agreement); except, in each of cases (i)– (iv), to the extent such
Liabilities result from a material breach of this Agreement by Sunesis, negligence or intentional misconduct of Sunesis or any of its agents or employees or failure of Sunesis or any of its employees or agents to comply with applicable laws or
regulations. 
 12.2 Sunesis. Sunesis agrees to indemnify, defend and hold harmless DOT-1 and
its Affiliates and their respective directors, officers, employees, agents and their respective heirs and assigns from and against any Liabilities resulting from any claims, demands, actions or other proceedings by any Third Party to the extent
resulting from: (i) the manufacture, use, sale, handling or storage of Reverted Licensed Products by Sunesis or its Affiliates or Sublicensees or other designees, (ii) the breach by Sunesis of its representations and warranties made in
this Agreement or (ii) the negligence or intentional misconduct of Sunesis or any of its agents or employees or failure of Sunesis or any of its agents or employees to comply with applicable laws and regulations; except, in each case, to the
extent such Liabilities result from a breach of this Agreement by DOT-1, negligence or intentional misconduct of DOT-1 or any of its agents or employees or failure of
DOT-1 or any of its employees or agents to comply with applicable laws or regulations. 

  
 24 

 12.3 Procedure. If a Party (the “Indemnitee”) intends to claim
indemnification under this Article 12, it shall promptly notify the other Party (the “Indemnitor”) in writing of any claim, demand, action or other proceeding for which the Indemnitee intends to claim such indemnification, and the
Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, to assume the defense thereof with counsel mutually satisfactory to the Parties; provided, however, that an Indemnitee shall have the right to retain
its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between the Indemnitee and
any other Party represented by such counsel in such proceeding. The obligations of this Article 12 shall not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of
the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such
action, shall relieve the Indemnitor of any obligation to the Indemnitee under this Article 12. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any claim,
demand, action or other proceeding covered by this Article 12. The Indemnitor shall not, without the Indemnitee’s consent, which consent shall not be withheld or delayed unreasonably, consent to the entry of any judgment or accept any
settlement with respect to such claim, demand, action or proceeding which imposes liability not covered by this indemnification or restrictions on the Indemnitee. 

ARTICLE 13 
 TERM AND
TERMINATION 
 13.1 Term. 

13.1.1 The Raf Agreement shall be amended and restated and superseded by this Agreement on the Effective Date. 

13.1.2 The term of this Agreement shall commence on the Effective Date, and shall continue in full force and effect on a country-by-country and Product-by-Product basis until expiration of both Parties’ royalty
payment obligations in such country with respect to such Products, in each case unless earlier terminated as provided in this Article 13 (the “Term”). Upon expiration of the Term, the licenses granted to DOT-1 and Sunesis in this Agreement shall become fully paid-up, royalty-free, perpetual and irrevocable. 

13.2 Termination for Breach. Either Party to this Agreement may terminate this Agreement, with respect to the applicable compounds and
products only, in the event the other Party hereto shall have materially breached or defaulted in the performance of any of its material obligations hereunder with respect to any Licensed Product(s), Licensed Compound(s) or Reverted Licensed
Product(s), and such default shall have continued for [*] after written notice thereof was provided to the breaching Party by the non-breaching Party. Such termination shall be specifically limited to the
compounds and products to which the breach or default relates, and this Agreement 

  
 25 

 
shall continue in full force and effect with respect to any other Licensed Product, Licensed Compound or Reverted Licensed Product. Any termination shall become effective at the end of such [*]
period unless the breaching Party has cured any such breach or default prior to the expiration of the [*] period. Notwithstanding the foregoing, failure by either Party to use Commercially Reasonable and Diligent Efforts with respect to the
development and commercialization of a Product shall not be deemed a breach of this Agreement. 
 13.3 Termination For Bankruptcy.
Either Party hereto shall have the right to terminate this Agreement forthwith by written notice to the other Party (i) if the other Party is declared insolvent or bankrupt by a court of competent jurisdiction, (ii) if a voluntary or
involuntary petition in bankruptcy is filed in any court of competent jurisdiction against the other Party and such petition is not dismissed within [*] after filing, (iii) if the other Party shall make or execute an assignment of substantially
all of its assets for the benefit of creditors, or (iv) substantially all of the assets of such other Party are seized or attached and not released within [*] thereafter. All rights and licenses granted under this Agreement by one Party to the
other Party are, and shall otherwise be deemed for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 (56) of the Bankruptcy Code. The Parties agree that
the licensing Party under this Agreement shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code in the event of a bankruptcy by the other Party. The Parties further agree that in the event of the commencement
of a bankruptcy proceeding by or against one Party under the Bankruptcy Code, the other Party shall be entitled to complete access to any such intellectual property pertaining to the rights granted in the licenses hereunder of the Party by or
against whom a bankruptcy proceeding has been commenced and all embodiments of such intellectual property. 
 13.4 Termination for
Convenience. Provided that DOT-1 is not in breach of this Agreement, DOT-1 will have the right to terminate this Agreement at any time with respect to any or all of
the Licensed Compounds and Licensed Products, by providing [*] prior written notice. In such event, this Agreement will remain in effect with respect to Reverted Licensed Products and any other Licensed Compound or Licensed Product, in each case
that has not been terminated. Provided that Sunesis is not in breach of this Agreement, Sunesis will have the right to terminate this Agreement at any time with respect to any or all of the Reverted Licensed Products, by providing [*] prior written
notice. In such event, this Agreement will remain in effect with respect to Licensed Compounds and Licensed Products and any other Reverted Licensed Products, in each case that has not been terminated. 

13.5 Effect of Breach or Termination. 

13.5.1 Accrued Rights and Obligations. Termination of this Agreement for any reason shall not release either Party hereto from any
liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law
or in equity with respect to any breach of this Agreement. 

  
 26 

 13.5.2 Termination by DOT-1 for Bankruptcy of
Sunesis. In the event of termination of this Agreement by DOT-1 pursuant to Section 13.3 for Sunesis’s bankruptcy, in addition to those provisions surviving under Section 13.8, the following
shall apply: 
 (a) Sections 5.1.3 (License for Reverted Licensed Products) (but only with respect to Reverted Licensed Products in
existence as of the effective date of such termination); (Development Milestones); 6.3 (Royalties on Annual Net Sales of Licensed Products) (except that any royalties payable by DOT-1 thereunder, commencing
upon such termination and continuing thereafter, shall be reduced by [*]); 6.4 (Royalties on Net Sales of Reverted Licensed Products); 6.5 (Royalty Term); Article 9 (Intellectual Property) (other than Sections 9.2.2 and 9.2.3, which shall terminate
except to the extent expressly set forth in Section 13.5.2(b) below); and Exhibit 8.2 (Reverted Licensed Products) (but only with respect to Reverted Licensed Products in existence as of the effective date of such termination) shall survive.

 (b) The prosecution rights that DOT-1 has pursuant to Section 9.2.2 shall survive. Sunesis
shall be given the opportunity to review DOT-1’s activities and reasonably consult with DOT-1 with respect to such Sunesis Collaboration Patents and Joint
Collaboration Patents, and DOT-1 shall in good faith consider including in such patent applications such claims as Sunesis reasonably requests. DOT-1 shall keep Sunesis
reasonably informed as to the status of such patent matters, including by providing Sunesis with (i) copies of any documents relating to such Sunesis Licensed Patents, Sunesis Collaboration Patents and Joint Collaboration Patents which DOT-1 receives from any patent office within [*] of receipt thereof, including notice of all interferences, reissues, reexaminations, oppositions or requests for patent term extensions, and (ii) the opportunity
to review and comment on any documents relating to such Sunesis Licensed Patents, Sunesis Collaboration Patents and Joint Collaboration Patents which will be filed in any patent office as soon practicable but in all cases at least [*] prior to such
filing. In conducting the prosecution activities described in this Section 13.5.2(b), each Party shall employ reasonable efforts not to substantially negatively impact the other Party’s rights under the surviving provisions of this
Agreement. 
 13.5.3 Termination by Sunesis for Breach or Bankruptcy of DOT-1. In the event
of any termination by Sunesis pursuant to Section 13.2 due to DOT-1’s breach (only with respect to the Licensed Compounds, Licensed Products and Raf Target) or pursuant to Section 13.3 for DOT-1’s bankruptcy, in addition to those provisions surviving under Section 13.8, the following provisions of this Section 13.5.3 shall apply: 

(a) 5.1.3 (License for Reverted Licensed Products); 6.2 (Development Milestones); 6.3 (Royalties on Annual Net Sales of Licensed Products);
6.4 (Royalties on Net Sales of Reverted Licensed Products (except that any royalties payable by Sunesis thereunder, commencing upon such termination and continuing thereafter, shall be reduced by [*]); 6.5 (Royalty Term); Article 8 (Diligence);
Article 9 (Intellectual Property) (other than Sections 9.2.2 and 9.2.3, which shall terminate); and Exhibit 8.2 (Reverted Licensed Products) shall survive, in addition to those provisions surviving under Section 13.8. 

(b) DOT-1 shall control prosecution of all the DOT-1
Collaboration Patents at its own expense, only for such Patent Rights that are related to the Raf Target, Licensed Compounds and Licensed Products. Sunesis shall control prosecution of all Sunesis Collaboration Patents and Joint Collaboration
Patents at its own expense for such Sunesis Collaboration Patents and Joint Collaboration Patents that are related to the Raf Target, Licensed Compounds and Licensed Products, as the case may be. DOT-1 shall
be given the opportunity to review Sunesis’s activities and reasonably consult with Sunesis with respect to such Joint Collaboration Patents, 

  
 27 

 
and Sunesis shall in good faith consider including in such patent applications such claims as DOT- 1 reasonably requests. Sunesis shall keep DOT-1 reasonably informed as to the status of such patent matters, including by providing DOT-1 with (i) copies of any documents relating to such Joint Collaboration
Patents which Sunesis receives from any patent office within [*] of receipt thereof, including notice of all interferences, reissues, reexaminations, oppositions or requests for patent term extensions, and (ii) the opportunity to review and
comment on any documents relating to such Joint Collaboration Patents which will be filed in any patent office as soon practicable but in all cases at least [*] prior to such filing. In conducting the prosecution activities described in this
Section 13.5.3(b), each Party shall employ reasonable efforts not to substantially negatively impact the other Party’s rights under the surviving provisions of this Agreement. 

(c) Subject to Section 5.1.2, each Licensed Product shall become a Reverted Licensed Product in accordance with Section 8.2 and
Exhibit 8.2 and Sunesis shall thereafter pay royalties to DOT-1 on Net Sales of such Reverted Licensed Product in accordance with Section 6.4 (except that any royalties payable by Sunesis thereunder,
commencing upon such termination and continuing thereafter, shall be reduced by [*]. 
 13.6 Termination by DOT-1 for Convenience. In the event of termination of this Agreement by DOT-1 pursuant to Section 13.4, in addition to those provisions surviving under
Section 13.8, the following shall apply: 
 13.6.1 Sections 5.1.3 (License for Reverted Licensed Products); 6.2 (Development
Milestones); 6.3 (Royalties on Annual Net Sales of Licensed Products); 6.4 (Royalties on Net Sales of Reverted Licensed Products) (except that any royalties payable by Sunesis thereunder, commencing upon such termination and continuing thereafter,
shall be reduced by [*]); Section 6.5 (Royalty Term); Article 8 (Diligence); Article 9 (Intellectual Property) (other than Sections 9.2.2 and 9.2.3, which shall terminate); and Exhibit 8.2 (Reverted Licensed Products) shall survive, in addition
to those provisions surviving under Section 13.8. 
 13.6.2 DOT-1 shall control prosecution of
all the DOT-1 Collaboration Patents at its own expense, only for such Patent Rights that are related to the Raf Target, Licensed Compounds and Licensed Products. Sunesis shall control prosecution of all
Sunesis Collaboration Patents and Joint Collaboration Patents at its own expense for such Sunesis Collaboration Patents and Joint Collaboration Patents that are related to the Raf Target, Licensed Compounds and Licensed Products, as the case may be.
DOT-1 shall be given the opportunity to review Sunesis’s activities and reasonably consult with Sunesis with respect to such Joint Collaboration Patents, and Sunesis shall in good faith consider including
in such patent applications such claims as DOT-1 reasonably requests. Sunesis shall keep DOT-1 reasonably informed as to the status of such patent matters, including by
providing DOT-1 with (i) copies of any documents relating to such Joint Collaboration Patents which Sunesis receives from any patent office within [*] of receipt thereof, including notice of all
interferences, reissues, reexaminations, oppositions or requests for patent term extensions, and (ii) the opportunity to review and comment on any documents relating to such Joint Collaboration Patents which will be filed in any patent office
as soon practicable but in all cases at least [*] prior to such filing. In conducting the prosecution activities described in this Section 13.6.2, each Party shall employ reasonable efforts not to substantially negatively impact the other
Party’s rights under the surviving provisions of this Agreement. 

  
 28 

 13.6.3 Subject to Section 5.1.2, each Licensed Product shall become a Reverted Licensed
Product in accordance with Section 8.2 and Exhibit 8.2 and Sunesis shall thereafter pay royalties to DOT-1 on Net Sales of such Reverted Licensed Product in accordance with Section 6.4 (except that
any royalties payable by Sunesis thereunder, commencing upon such termination and continuing thereafter, shall be reduced by [*]). 
 13.7
Transition of Information and Materials. With respect to a Party’s obligation to transition Collaboration Technology, information and material with respect to a particular Licensed Compound, each Party shall cooperate fully (and cause
its Affiliates to cooperate fully) with the other Party to facilitate a smooth and prompt transition of Collaboration Technology, information and materials that are necessary or useful for the receiving Party to exercise its licensed rights
hereunder with respect to such Licensed Compound. 
 13.8 Survival Sections. In addition to the provisions set forth in Sections
13.5.2, 13.5.3 and 13.6 above, as applicable, the following provisions shall survive the expiration or termination of this Agreement for any reason: Articles 1 (Definitions), 7 (Payments, Books and Records), 10 (Confidentiality), 11 (Representations
and Warranties), 12 (Indemnification), 13 (Term and Termination), 14 (Dispute Resolution) and 15 (Miscellaneous); and Sections 5.1.1 and 5.1.2. 

ARTICLE 14 
 DISPUTE
RESOLUTION 
 14.1 Escalation to Senior Executives. In the event of a dispute or matter of significant concern arises between the
Parties, then at the request of either Party, the matter shall be escalated to a senior executive from each Party. Such senior executive shall be either the CEO or President of such Party, or another senior executive of such Party with the title of
Vice President or higher and who has direct management responsibility for the matter in dispute. Upon such request, such senior executives shall make themselves reasonably available to meet, and shall meet either by telephone or if, specifically
requested, in person, to attempt to resolve such matter, and shall thereafter continue to use good faith efforts to attempt to resolve such matter unless it becomes clear that the matter cannot be resolved by mutual agreement. Thereafter either
Party may pursue such legal process as is otherwise available under applicable law. 
 14.2 Injunctive Relief. This Article 14 shall
not be construed to prohibit either Party from seeking preliminary or permanent injunctive relief, restraining order or degree of specific performance in any court of competent jurisdiction to the extent not prohibited by this Agreement. For
avoidance of doubt, any such equitable remedies provided under this Article 14 shall be cumulative and not exclusive and are in addition to any other remedies, which either Party may have under this Agreement or applicable law. 

14.3 Matters to Proceed to Court. Notwithstanding the foregoing, any dispute relating to the determination of validity of a
Party’s patents or other issues relating solely to a Party’s intellectual property and any dispute asserting breach of this Agreement or of the representations and warranties made hereunder shall be submitted exclusively to the federal
court in Delaware, and the Parties hereby consent to the jurisdiction and venue of such court. 

  
 29 

 ARTICLE 15 

MISCELLANEOUS 
 15.1
Governing Laws. This Agreement and any dispute arising from the construction, performance or breach hereof shall be governed by and construed, and enforced in accordance with, the laws of the state of Delaware, without reference to conflicts
of laws principles. 
 15.2 Waiver. It is agreed that no waiver by either Party hereto of any breach or default of any of the
covenants or agreements herein set forth shall be deemed a waiver as to any subsequent or similar breach or default. 
 15.3
Assignment. This Agreement shall not be assignable by either Party without the written consent of the other Party hereto, except either Party may assign this Agreement without such consent to its Affiliates, or to an entity that acquires all
or substantially all of the business or assets of such Party whether by merger, reorganization, acquisition, sale, or otherwise; provided, however, that the assignee shall agree in writing to be bound by the terms and conditions of this Agreement,
and that in the case of such an acquisition of all or substantially all of the business or assets of a Party, such assignment shall take effect upon written notice of such acquisition to the other Party. In addition,
DOT-1 shall have the right to assign this Agreement to Millennium in connection with a Millennium Reversion. Notwithstanding any other provision in this Agreement, an assignment or Change of Control
transaction involving Sunesis shall not be deemed to be a breach of this Agreement or otherwise require the acquirer or surviving entity following the Change of Control transaction to divest any products or research programs directed against a Raf
Target which products or programs were being researched, developed or commercialized by the relevant Third Party acquirer prior to such assignment or Change of Control (a “Competing Program”), provided that such acquiror or
surviving entity shall implement and enforce written processes and procedures to ensure that employees and other individuals working on or involved in the Competing Program shall not use or have access to the Sunesis Licensed Patents with respect
to: the Raf Target, Licensed Compounds and Licensed Products; DOT-1 Collaboration Patents; Joint Collaboration Patents; Development Technology; Other DOT-1 Technology;
and Confidential Information of DOT-1. 
 15.4 Independent Contractors. The relationship of
the Parties hereto is that of independent contractors. The Parties hereto are not deemed to be agents, partners or joint venturers of the others for any purpose as a result of this Agreement or the transactions contemplated thereby. 

15.5 Compliance with Laws. In exercising their rights under this license, the Parties shall fully comply in all material respects with
the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this license including those applicable to the development, manufacture, distribution,
import and export and sale of Licensed Products pursuant to this Agreement. 
 15.6 Patent Marking.
DOT-1 agrees to mark and use reasonable efforts to make all its Sublicensees mark all Licensed Products sold pursuant to this Agreement in accordance with the applicable statute or regulations relating to
patent marking in the country or countries of manufacture and sale thereof. Sunesis agrees to mark and use reasonable efforts to make its Sublicensees mark all Reverted Licensed Products sold pursuant to this Agreement in accordance with the
applicable statute or regulations relating to patent marking in the country or countries of manufacture and sale thereof. 

  
 30 

 15.7 Notices. All notices, requests and other communications hereunder shall be in
writing and shall be personally delivered or by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in writing to the other
Parties hereto and shall be deemed to have been given upon receipt: 
  

			
	Sunesis:	  	 Sunesis Pharmaceuticals, Inc.
 [*]

 

	With a copy to:            	  	 Cooley LLP
 [*]

 

	DOT-1	  	 DOT Therapeutics-1, Inc.

[*]

 15.8 Severability. In the event that any provision of this Agreement becomes or is declared by a court
of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision, and the Parties shall amend the Agreement to the extent feasible to
lawfully include the substance of the excluded term to as fully as possible realize the intent of the Parties and their commercial bargain. If a Party seeks to avoid a provision of this Agreement by asserting that such provision is invalid, illegal
or otherwise unenforceable, the other Party shall have the right to terminate this Agreement upon [*] prior written notice to the asserting Party, unless such assertion is eliminated and cured within such [*] period. If DOT-1 has sought to so avoid a provision of this Agreement, such termination shall be deemed a termination by DOT-1 under Section 13.4 above, and if Sunesis has sought
such an avoidance, such termination shall be deemed a termination by DOT-1 for breach by Sunesis under Section 13.2 above. 

15.9 Advice of Counsel. Sunesis and DOT-1 have each consulted counsel of their choice regarding
this Agreement, and each acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and will be construed accordingly. 

15.10 Performance by Affiliates; Warranty. DOT-1 may exercise any right or discharge any
obligation hereunder through any of its Affiliates. Each Party hereby warrants and guarantees the performance of any and all rights and obligations of this Agreement by its Affiliates and Sublicensees. 

15.11 Complete Agreement. This Agreement with its Exhibits, constitutes the entire agreement, both written and oral, between the
Parties with respect to the subject matter hereof, and all prior agreements, including the CDA, respecting the subject matter hereof, either written or oral, express or implied, shall be abrogated, canceled, and are null and void and of no effect.
No amendment or change hereof or addition hereto shall be effective or binding on either of the Parties hereto unless reduced to writing and executed by the respective duly authorized representatives of Sunesis and
DOT-1. 

  
 31 

 15.12 Amendment and Restatement. This Agreement constitutes an amendment and
restatement of the Raf Agreement effective from and after the Effective Date. As of the Effective Date, the 2014 Amended and Restated Agreement is hereby amended, supplemented, modified and restated in its entirety as described herein. 

15.13 Headings. The captions to the several Sections and Articles hereof are not a part of this Agreement, but are included merely for
convenience of reference and shall not affect its meaning or interpretation. 
 15.14 Counterparts. This Agreement may be executed in
counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. This instrument may be executed by facsimile or electronically transmitted signatures and such signatures shall
be deemed to bind each Party hereto as if they were original signatures. 
 * * * * * 

  
 32 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by
their authorized representatives and delivered in duplicate originals as of the Effective Date. 
  

									
	DOT-1 THERAPEUTICS, INC.	 		 	SUNESIS PHARMACEUTICALS, INC.
					
	By:	 	/s/ Julie P. Grant	 		 	By:	 	/s/ William Quinn
					
	Name:	 	Julie Grant	 		 	Name:	 	 William Quinn

					
	Title:	 	Chief Executive Officer	 		 	Title:	 	Chief Financial Officer

  
 -Signature Page- 

 EXHIBIT 1.14 

DOT-1 Collaboration Patents 

 EXHIBIT 1.18 

Joint Collaboration Patents 

 EXHIBIT 1.37 

Sunesis Collaboration Patents 

 EXHIBIT 1.38 

Sunesis Licensed Patents 

 EXHIBIT 8.2 

Reverted Licensed ProductEX-10.7

 Exhibit 10.7 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT
THE 
 REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. 

LICENSE AGREEMENT 

dated February 10, 2021 

by and between 
 Merck
KGaA 
 and 
 Day
One Biopharmaceuticals, Inc. 

  
 1 

 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is entered into as of February 10, 2021 (the “Effective
Date”) by and between: 
  

	(1)	 Merck KGaA, a corporation with general partners organized under the laws of Germany, located at
Frankfurter Straße 250, 64293 Darmstadt, Germany (“MRKDG”); and 

  

	(2)	 Day One Biopharmaceuticals, Inc., a corporation organized under the laws of Delaware, located at 395
Oyster Point Boulevard, Suite 217, San Francisco, CA 94080, USA (“Company”). 

 MRKDG and Company each
may be referred to herein individually as a “Party” or collectively as the “Parties.” 
 RECITALS

 WHEREAS, MRKDG is engaged, among other activities, in the development of pharmaceutical products and is the holder of several
rights in the Compounds (as defined below); 
 WHEREAS, MRKDG wishes to license to Company, on an exclusive basis, the right to
Research, Develop, manufacture and Commercialize products comprising the Compounds in the Field (as each such capitalized term is defined below); 

NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, the Parties agree to as follows. 

ARTICLE 1 DEFINITIONS 

For purposes of this Agreement, the following capitalized terms will have the following meanings: 

1.1 “Accounting Standards” means GAAP or IFRS, as generally and consistently applied by the relevant party. 

1.2 “Acquired COC Program” has the meaning set forth in Section 11.7. 

1.3 “Acquiring Person COC Program” has the meaning set forth in Section 11.7. 

1.4 “Action” has the meaning set forth in Section 7.4(b).“Affiliate” means
a Person that controls, is controlled by or is under common control with another Person, but only for so long as such control exists. For the purposes of this Section, the word “control” (including, with correlative meaning, the
terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person,
whether by the ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. 
 1.5
“Agreement” has the meaning set forth in the preamble. 
 1.6 “Alliance Manager” has the meaning
set forth in Section 4.2. 
 1.7 “ANDA Filing” has the meaning set forth in
Section 7.6. 
 1.8 “Applicable Laws” means any applicable supranational, federal, state,
local or foreign law, statute, ordinance or principle of common law, or any rule, regulation, standard, judgment, order, writ, injunction, decree, arbitration award, agency guidelines or other requirement, license or permit of any Governmental Body,
which may be in effect from time to time. 

  
 2 

 1.9 “Approval Application” means an NDA or similar application or
submission for a Product filed with a Regulatory Authority in a country or group of countries to obtain marketing approval for a biological or pharmaceutical product in that country or group of countries. 

1.10 “Business Day” means a day other than Saturday or Sunday on which banking institutions in New York, New York,
Vaud, Switzerland and Darmstadt, Germany are open for business. 
 1.11 “Calendar Quarter” means each three
(3) month period commencing January 1, April 1, July 1 or October 1; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first full Calendar
Quarter thereafter, and (b) the last Calendar Quarter of the Term shall end on the date of termination or expiration of this Agreement. 

1.12 “Calendar Year” means the period beginning on January 1 and ending on December 31 of the same year;
provided, however, that (a) the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the same year and (b) the last Calendar Year of the Term shall commence on January 1 of the
Calendar Year in which this Agreement terminates or expires and end on the date of termination or expiration of this Agreement. 

1.13 “Change of Control” means, with respect to a Person: [*]. 

1.14 [*]. 
 1.15
“Clinical Trial” means a clinical trial in human subjects that has been approved by a Regulatory Authority and institutional review board or ethics committee and is designed to measure the safety or efficacy of a
pharmaceutical product. Clinical Trials shall include Phase I Trials, Phase II Trials and Phase III Trials. 
 1.16
“Code” has the meaning set forth in Section 11.5. 
 1.17 “Commercial Milestone
Event” means each of the milestone events listed in Section 6.2(b). 
 1.18 “Commercial
Milestone Payment” has the meaning set forth in Section 6.2(b). 
 1.19
“Commercialization,” “Commercializing,” or “Commercialize” means any and all activities undertaken before or after Regulatory Approval of an NDA for a particular
Product and directed to the commercial exploitation of the Product, including the marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of the Product, and interacting with Regulatory Authorities
regarding the foregoing. 
 1.20 “Commercialization Plan” has the meaning set forth in
Section 3.2(b). 
 1.21 “Commercially Reasonable Efforts” means, [*]. 

1.22 “Company” shall have the meaning set forth in the preamble. 

1.23 “Company Patents” has the meaning set forth in Section 7.2(a). 

1.24 “Company Publication” has the meaning set forth in Section 8.2. 

1.25 “Competing Product” means [*]. 

  
 3 

 1.26 “Compound” means either (i) the MEK inhibitor known
as MSC1936369B and as Pimasertib (“Pimasertib”), or (ii) the MEK inhibitor known as MSC2015103B (“103B”), in each case as described in Schedule 1.26.
“Compounds” means both Pimasertib and 103B. 
 1.27 “Compound Inventory” means the inventory of
each Compound existing at MRKDG’s facilities as at the Effective Date, except for inventory of Pimasertib reserved to complete the Existing Clinical Study and for the continued treatment of patients participating in the Existing Clinical Study.
The Compound Inventory is listed in Schedule 1.27. 
 1.28 “Confidential
Information” of a Party means information relating to the business, operations or products of such Party or any of its Affiliates, including any Know-How that such Party discloses to the other
Party under this Agreement, or otherwise becomes known to the other Party by virtue of this Agreement. 
 1.29
“Control” or “Controlled” means, with respect to (a) Patent Rights, (b) Know-How or (c) biological, chemical or physical material, that the Party or one of its
Affiliates owns or has a license or sublicense to such right, item, or material (or in the case of material, has the right to physical possession of such material) and has the ability to grant a license or sublicense to, or assign its right, title
and interest in and to, such right, item or material as provided for in this Agreement without violating the terms of any agreement or other arrangement with any Third Party, in particular such Third Party that has assigned or licensed such Patent
Rights, Know-How or material to such Party (or any Affiliate of such Party). 
 1.30
“Data Protection Law” means the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free
movement of such data, and repealing Directive 95/46/EC (the “General Data Protection Regulation”) as well as, if applicable, any other data protection laws of the country in which Company is established and any data protection laws
applicable to Company in connection with this Agreement. “Personal Data” as used in this Agreement shall mean any information relating to an identified or identifiable natural person as defined in the General Data Protection
Regulation. 
 1.31 “Development” means, with respect to a Compound or Product, all clinical and non-clinical research and development activities conducted after filing of an IND for such Compound or Product, including toxicology, pharmacology test method development and stability testing, process development,
formulation development, delivery system development, quality assurance and quality control development, statistical analysis, Clinical Trials (other than post-Marketing Approval Clinical Trials), regulatory affairs, pharmacovigilance, Clinical
Trial regulatory activities and obtaining and maintaining Marketing Approval. When used as a verb, “Develop,” “Developed,” or “Developing” means to engage in Development. 

1.32 “Development Plan” shall have the meaning set forth in Section 3.1(b). 

1.33 “EMA” means the European Medicines Agency, or any successor agency thereto. 

1.34 “European Commission” means the authority within the European Union that has the legal authority to grant
Regulatory Approvals in the European Union based on input received from the EMA or other competent Regulatory Authorities. 
 1.35
“European Union” or “EU” means the European Union, as may be redefined from time to time. 
 1.36
“Existing Clinical Studies” means the clinical studies conducted under the Existing License which are listed in Schedule 1.36. 

  
 4 

 1.37 “Existing License” means that certain Strategic Collaboration
Agreement between Ares Trading S.A., with place of business at Z.I de l’Ouriettaz, CH-1170 Aubonne, Switzerland (“ATSA”), an Affiliate of MRKDG, and the Existing Licensee dated
November 21, 2016, as amended, and the Study Order No. 14 thereunder dated March 1, 2020, pursuant to which ATSA has granted certain non-exclusive rights and licenses to [*], an electronic,
redacted copy of which was made available to Company. 
 1.38 “Existing Licensee” means [*]. 

1.39 “FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules and
regulations promulgated thereunder. 
 1.40 “FDA” means the United States Food and Drug Administration, or
any successor agency thereto. 
 1.41 “Field” means all prophylactic, palliative, therapeutic or diagnostic
uses in humans or animals in all Indications. 
 1.42 “First Commercial Sale” means the first sale or commercial
transfer or disposition for value of the Product to a Third Party by Company, its Affiliates or Sublicensees. 
 1.43
“FTE” means [*] devoted to activities under this Agreement, including providing cooperation, assistance or support to MRKDG under this Agreement, that is carried out by one or more qualified employees of MRKDG or its Affiliates.
[*]. 
 1.44 “FTE Rate” means [*]. 

1.45 “Governmental Body” means any (a) nation, principality, state, commonwealth, province, territory,
county, municipality, district, or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign, or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division,
subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body, or entity and any court or other tribunal); (d) multi-national or supranational
organization or body; or (e) individual, entity, or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military, or taxing authority or power of any nature. 

1.46 “IFRS” means the International Financial Reporting Standards set of accounting standards and interpretations and
the framework in force on the Effective Date and adopted by the European Union as issued by the International Accounting Standards Board and the International Financial Reporting Interpretations Committee, as such accounting standards may be amended
from time to time. 
 1.47 “Improper Conduct” has the meaning set forth in Section 13.1.

 1.48 “IND” means an investigational new drug application filed with the FDA or the equivalent application
or filing filed with any equivalent agency or Governmental Body outside the United States (including any supra-national entity such as in the European Union) for approval to commence Clinical Trials in such jurisdiction, and including all
regulations at 21 U.S. CFR § 312 et seq. and equivalent foreign regulations. 
 1.49 “Indemnified Party” has
the meaning set forth in Section 10.3. 
 1.50 “Indemnifying Party” has the meaning set
forth in Section 10.3. 

  
 5 

 1.51 “Indication” means a generally acknowledged disease or
condition, a significant manifestation of a disease or condition, or symptoms associated with a disease or condition, or a risk for a disease or condition for which an NDA may be obtained. 

1.52 “Know-How” means any: (a) scientific or technical
information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, that is not in the public domain or otherwise publicly known, including discoveries, inventions, trade secrets, devices, databases, practices,
protocols, regulatory filings, methods, processes (including manufacturing processes, specification and techniques), techniques, concepts, ideas, specifications, formulations, formulae, data (including pharmacological, biological, chemical,
toxicological, clinical and analytical information, quality control, trial and stability data), case reports forms, medical records, data analyses, reports, studies and procedures, designs for experiments and tests and results of experimentation and
testing (including results of research or development), summaries and information contained in submissions to and information from ethical committees, or Regulatory Authorities, and manufacturing process and development information, results and
data, whether or not patentable; and (b) compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material, including drug substance samples, intermediates of drug substance samples, drug product
samples and intermediates of drug product samples. The fact that an item is known to the public shall not be taken to exclude the possibility that a compilation including the item, or a development relating to the item, is (and remains) not known to
the public. “Know-How” includes any rights including copyright, database or design rights protecting such Know-How.
“Know-How” excludes Patent Rights. 
 1.53 “Detailed Asset Transfer
Plan” has the meaning set forth in Section 2.5(a). 
 1.54 “Licensee Indemnitees”
has the meaning set forth in Section 10.1. 
 1.55 “Losses” has the meaning set forth in
Section 10.1. 
 1.56 “Major Asian Market” means [*]. 

1.57 “Major Market” means any of [*]. 

1.58 “Marketing Approval” or “MA” means, with respect to a Product in a particular jurisdiction, all
approvals, licenses, registrations, or authorizations necessary for the Commercialization of such Product in such jurisdiction, including, with respect to the United States, approval of an Approval Application for such Product by the FDA and with
respect to the European Union, approval of an Approval Application for such Product by the European Commission or the applicable Regulatory Authority in any particular country in the EU. [*]. 

1.59 “Milestone Payment” shall have the meaning set forth in Section 6.2(a). 

1.60 “MRKDG” shall have the meaning set forth in the preamble. 

1.61 “MRKDG Indemnitees” has the meaning set forth in Section 10.2. 

1.62 “MRKDG Know-How” means all
Know-How specifically related to the Compounds that is owned or Controlled by MRKDG as of the Effective Date and is necessary for the Research, Development, manufacture, use, or Commercialization of the
Compounds or Products in the Field, including, without limitation, the Know-How as described on Schedule 2.5 hereto. For clarity, “MRKDG
Know-How” does not include Know-How that is generated under the Existing License from the conduct of the Existing Clinical Studies (“Excluded Know-How”). 
 1.63 “MRKDG Patents” means the Patent Rights set forth on
Schedule 1.63 hereto. 

  
 6 

 1.64 “MRKDG Technology” means the MRKDG Know-How and the MRKDG Patents, collectively. 
 1.65 “NDA” means a New Drug
Application filed pursuant to the requirements of the FDA, as more fully defined in 21 U.S. CFR § 314.3 et seq., a Biologics License Application filed pursuant to the requirements of the FDA, as more fully defined in 21 U.S. CFR
§ 601, and any equivalent application submitted in any country in the Territory, including all additions, deletions or supplements thereto, and as any and all such requirements may be amended, or supplanted, at any time. 

1.66 “Net Sales” means [*]. 

1.67 “Party” or “Parties” shall have the meaning set forth in preamble. 

1.68 “Patent Right(s)” means (a) all national, regional and international patents and patent applications,
including provisional patent applications, (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals,
continuations, continuations-in-part, converted provisionals and continued prosecution applications, (c) any and all patents that have issued or in the future issue
from the foregoing patent applications ((a) and (b)), including utility models, petty patents and design patents and certificates of invention, (d) any and all extensions or restorations by existing or future extension or restoration
mechanisms, including revalidations, renewals, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications set
forth in clauses (a), (b), and (c). 
 1.69 “Person” means any natural person,
corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or agency or political subdivision thereof. 

1.70 “Phase I Trial” means a Clinical Trial in which the Product is administered to human subjects at multiple dose
levels with the primary purpose of determining safety, metabolism, and pharmacokinetic and pharmacodynamic properties of the Product, and consistent with 21 U.S. CFR § 312.21(a). 

1.71 “Phase II Trial” means a Clinical Trial of the Product in human patients, the principal purposes of which
are to make a preliminary determination that the Product is safe for its intended use, to determine its optimal dose, and to obtain sufficient information about the Product’s efficacy to permit the design of Phase III Trials, and consistent
with 21 U.S. CFR 312.21(b). 
 1.72 “Phase III Trial” means a human Clinical Trial of the Product, which
trial is designed (a) to establish that the Product is safe and efficacious for its intended use; (b) to define warnings, precautions and adverse reactions that are associated with the Product in the dosage range to be prescribed; and
(c) consistent with 21 U.S. CFR § 312.21(c). 
 1.73 “Price Approval” means, in any country where a
Governmental Body authorizes reimbursements for, or approves or determines pricing for, pharmaceutical products with respect to public or private payors, receipt (or, if required to make such authorization, approval or determination effective,
publication) of such reimbursement authorization or pricing approval or determination for any such payor or group of payors. 
 1.74
“Product” means any pharmaceutical product, including any dosage form or formulation thereof, that contains or comprises, in whole or in part, a Compound. 

1.75 “Regulatory Approval” means any and all approvals, licenses, registrations, or authorizations of the relevant
Regulatory Authority necessary for the Development, manufacture or Commercialization of a Product in a particular country or jurisdiction. For the purpose of the Milestone Payments, Regulatory Approval corresponds to the receipt of notice from the
relevant Regulatory Authority that the NDA filed for a Product with such Regulatory Authority meets the criteria for acceptance or, in the absence of such notice, the delivery of the Marketing Approval by the relevant Regulatory Authority. 

  
 7 

 1.76 “Regulatory Authority” means (a) in the US, the FDA,
(b) in the EU, the EMA or the European Commission, or (c) any Governmental Body with similar regulatory authority over pharmaceutical or biotechnology products in any other jurisdiction anywhere in the world. 

1.77 “Regulatory Materials” means, in consideration of the Development status of the Compound or Product, all
applicable regulatory registrations, applications, authorizations, approvals (including approvals of NDAs, supplements and amendments, pre- and post-approvals, Pricing Approvals and labeling approvals, and
INDs) and other submissions made to or with any Regulatory Authority, including drug master files, for Development (including the conduct of Clinical Trials), manufacture or Commercialization of a Compound or Product in a country or regulatory
jurisdiction, together with all related correspondence to or from any Regulatory Authority and all documents referenced in the complete regulatory chronology for each NDA, including any US Certificate of Pharmaceutical Product. 

1.78 “Regulatory Milestone Event” means each of the milestone events listed in
Section 6.2(a). 
 1.79 “Regulatory Milestone Payment” shall have the meaning set
forth in Section 6.2(a). 
 1.80 “Research” means conducting research activities to
discover, design, optimize, deliver and advance Compound and Products, including pre-clinical studies and optimization, but specifically excluding Development, manufacture, and Commercialization. When used as
a verb, “researching” means to engage in Research. 
 1.81 “Review Period” has the meaning set
forth in Section 8.2. 
 1.82 “Royalty Term” has the meaning set forth in
Section 6.3(c). 
 1.83 “Safety Data Exchange Agreement” has the meaning set forth in
Section 3.7(b). 
 1.84 [*]. 

1.85 “Selling Party” has the meaning set forth in Section 1.66. 

1.86 “Senior Officers” means a member of senior management of a Party who is designated by such Party to resolve
disputes under this Agreement. 
 1.87 “Sublicensee” means a Person to which Company has, pursuant to
Section 2.2, granted sublicense rights under any of the license rights granted under Section 2.1. 

1.88 “TC” shall have the meaning set forth in Section 4.1(a). 

1.89 “Term” shall have the meaning set forth in Section 11.1. 

1.90 “Terminated Product” has the meaning set forth in Section 11.8(g). 

1.91 “Territory” means all the countries in the world. 

1.92 “Third Party” means any Person other than Company, MRKDG, or their respective Affiliates. 

  
 8 

 1.93 “Third Party Action” has the meaning set forth in
Section 7.5(a). 
 1.94 “United States” or “US” means the United States
of America. 
 1.95 “USD” or “$” means the lawful currency of the United States. 

1.96 “Valid Claim” means a claim of a pending, or issued and unexpired patent which has not lapsed or been revoked,
abandoned or held unenforceable or invalid by a final decision of a court or Governmental Body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been disclaimed, denied or admitted to be
invalid or unenforceable through reissue, reexamination or disclaimer or otherwise. 
 1.97 “VAT” means value added
tax. 
 ARTICLE 2 GRANT OF LICENSE 

2.1 Grant of License. Subject to the terms and conditions of this Agreement, and subject to the rights granted to Existing
Licensee under the Existing License with respect to Pimasertib, MRKDG (on behalf of itself and its Affiliates) hereby grants to Company an exclusive (even as to MRKDG and its Affiliates), upfront-, milestone- and royalty-bearing right and license
(with the right to grant sublicenses through multiple tiers, subject to the provisions of Section 2.2) to Research, Develop, have Developed, make, have made, use, keep, sell, offer for sale, import, export, and Commercialize the Compounds and
Products in the Field in the Territory, under the MRKDG Technology. For clarity, the foregoing license grant includes the right to Research, Develop, have Developed, make, have made, use, keep, sell, offer for sale, import, export, and Commercialize
Products as monotherapies as well as for use in combination (including concomitant or sequential therapy lines) with other Company or Third Party proprietary products. 

2.2 Grant of Sublicense by Company. Effective commencing on the Effective Date, Company shall have the right to grant
sublicenses, in whole or in part, through multiple tiers, under the license granted in Section 2.1. Each such sublicense will be consistent with the terms of this Agreement and will require such Sublicensee to comply with
all applicable terms of this Agreement. Company will remain responsible for each Sublicensee’s compliance with the applicable terms of this Agreement. Within [*] after the grant of a sublicense, Company will provide a true copy of such
sublicense to MRKDG; provided, that such copy may be redacted except as necessary for MRKDG to ensure such sublicense complies with the terms hereof. 

2.3 Grant Back License. Effective commencing on the Effective Date, Company hereby grants to MRKDG a non-exclusive, royalty-free, fully-paid up, sublicensable, worldwide grant back license under the MRKDG Technology relating to Pimasertib solely as necessary to enable MRKDG’s and the Existing Licensee’s
use of such MRKDG Technology for completion of the ongoing Existing Clinical Studies. On an Existing Clinical Study-by-Existing Clinical Study basis, the foregoing grant
back license will terminate upon the termination or conclusion of such Existing Clinical Study. 
 2.4 Pre-Clinical Research Collaborations prior to the Effective Date. Notwithstanding anything stated herein to the contrary, Company appreciates that MRKDG has entered into preclinical collaborations with Third
Parties in the past, with respect to Pimasertib and 103B, including but not limited to those listed in Schedule 2.4. Based on the information available to the Parties as at the Effective Date, it is the Parties’ mutual
understanding that the Know-How generated in such collaborations is not necessary for the Development and Commercialization of Compounds and Products by Company after the Effective Date, and therefore not
included in the scope of this Agreement. Should either Party become aware, after the Effective Date, that any such Know-How is necessary for the Development and Commercialization of Compounds and Products by
Company, the Parties will collaborate in good faith regarding the inclusion of any such Know-How Controlled by MRKDG in this Agreement, and transfer of such Know-How to
Company. MRKDG will use 

  
 9 

 
Commercially Reasonable Efforts to provide Company with data Controlled by MRKDG resulting from such preclinical collaborations, which data, to the extent provided to Company, shall be included
in the definition of MRKDG Know-How, subject to the rights and licenses (in each case non-commercial only) granted to the collaboration partner, if any. Company further
acknowledges and agrees that such collaborations might result in publications by MRKDG or MRKDG’s collaboration partner still after the Effective Date. MRKDG will use Commercially Reasonably Efforts to bring such publication manuscripts to the
attention of Company prior to publication, and to work with the respective collaboration partner regarding an amendment of such manuscripts as desired by Company. 

2.5 Transfer. 

(a) Transfer of MRKDG Know-How. MRKDG shall transfer to Company all of the MRKDG Know-How, including the documents, databases and assets Controlled by MRKDG as listed in Schedule 2.5, pursuant to a detailed plan regarding the transfer of MRKDG
Know-How to Company (“Detailed Asset Transfer Plan”). The Parties shall use Commercially Reasonable Efforts to agree upon the Detailed Asset Transfer Plan within [*] after the Effective Date.
Such transfer shall take place in an orderly fashion and in a manner such the value, usefulness and confidentiality of the transferred MRKDG Know-How are preserved in all material respects. Notwithstanding the
foregoing, within [*] after the Effective Date, Company shall have in place a system to allow the transfer of global safety database ownership for the Products by MRKDG. Upon notification by Company of its readiness for safety database, the Parties
shall collaborate in good faith to initiate and complete the transfer of such global safety database for the Compounds to Company. Until the ownership of the global safety database is transferred to Company, upon Company’s request and subject
to Section 2.5(d), MRKDG will provide to Company assistance with inquiries from, and filings to, Regulatory Authorities that require access to the global safety database. If any MRKDG
Know-How resides at a MRKDG vendor (including, but limited to, contract research organizations and academic research institutions (excluding Existing Licensee)) and requires MRKDG to fulfill the transfer by
contacting that vendor, all requests and vendor contact will be originated and facilitated by MRKDG, with electronic copies (e.g., inclusion on emails) to Company. Upon the request of Company, MRKDG will introduce Company to any such Third Party
vendor and reasonably cooperate with Company’s efforts to enter into an agreement with such Third Party (if any). 
 (b) Regulatory
Transfer. Excluding any clinical trial agreements or other regulatory filings submitted to Regulatory Authorities relating solely to the Existing Clinical Trials, within [*] after the Effective Date, MRKDG shall assign to Company, at
Company’s cost and expense subject to Section 2.5(d), all applications and filings made by or on behalf of MRKDG with the FDA to enable transfer of ownership of the IND [*] to Company, with respect to the Compound or a
Product. Further details regarding such transfer will be specified in Schedule 2.5. 
 (c) Manufacturing Transfer. Without limiting
the foregoing, within [*] after the Effective Date, MRKDG and its Affiliates shall conduct or cause their Third Party subcontractors to conduct a transfer of documentation and knowledge of any manufacturing process(es) for the Compounds Controlled
by MRKDG as of the Effective Date, including by providing copies of such documents and information, as are necessary or reasonably useful to enable Company (or its designee) to conduct manufacturing of the Compounds and Products in accordance with
Applicable Law, which transfer shall be at Company’s cost subject to Section 2.5(d), except that transfer support assistance for the manufacturing transfer will be provided during [*]after the Effective Date. 

(d) Transfer Support Assistance. During the [*] after the Effective Date, upon Company’s request, MRKDG will provide to Company up
to [*] of assistance to support the transfer of MRKDG Know-How pursuant to Sections 2.5(a)-(c), including by MRKDG’s representatives participating in the TC in accordance with
Section 4.1 but solely to the extent such assistance involves providing scientific or technical assistance as well as support activities in context of Section 3.7 as required. In the event that
Company requires more than the aforementioned [*] of assistance, MRKDG shall provide such assistance at Company’s cost and expense subject to the FTE Rate and reasonable 

  
 10 

 
out of pocket expenses. In any case, Company shall provide reasonable advance notice to MRKDG on the need of assistance, and the Parties shall co-operate
in good faith to ensure that MRKDG’s assistance can be provided without undue disruption to either Party’s business needs. Without limiting the generality of the foregoing, for [*] following the Effective Date, MRKDG will provide Company
with access to MRKDG key contact persons who can answer questions on a limited basis in the areas of biology, pharmacology/DMPK, toxicology, regulatory, safety, clinical development, clinical operations, CMC, and medical affairs for the Compounds or
Products. 
 ARTICLE 3 RESEARCH, DEVELOPMENT AND COMMERCIALIZATION 

3.1 Research and Development of Product by Company. 

(a) Generally. Subject to the exception under Section 3.1(d), effective commencing on the Effective Date,
Company shall have the exclusive right and responsibility to manufacture, Research and Develop the Compounds and Products in any Indication in the Field in the Territory and to conduct (either itself or through its Affiliates, agents,
subcontractors, or Sublicensees) all Clinical Trials and non-clinical studies Company believes appropriate to obtain Regulatory Approval for the Products in any Indication in the Field in the Territory. 

(b) Development Plan. The Development of each Product shall be governed by a development plan which is attached to this Agreement as
Schedule 3.1, that describes the proposed overall program of Development, the Development assumptions, Development steps and personnel commitment of Company and which shall in particular include, in each case with estimated timelines
and milestones to be achieved by Company [*] (the “Development Plan”). 
 (c) Updates to Development Plan. Company
shall update and amend the Development Plan as appropriate, in Company’s sole discretion, acting in good faith. In case of any material change (as determined by Company, acting in good faith), Company shall provide the respective updated
Development Plan to MRKDG without delay. 
 (d) Existing Clinical Studies. Notwithstanding anything herein to the contrary, MRKDG
(itself or through its Affiliates or through any Third Party under contract with MRKDG as of the Effective Date with respect to the Existing Clinical Studies) shall have the right to complete the Existing Clinical Studies. For clarity, MRKDG (itself
or through its Affiliates or through any Third Party) may not initiate any new Clinical Trial for Pimasertib during the Term. MRKDG shall not and shall ensure that its Affiliates and Existing Sublicensee do not use any Excluded Know-How for the further Development or Commercialization of Pimasertib or any Product containing or comprising Pimasertib. 

3.2 Commercialization. 

(a) Subject to the terms and conditions of this Agreement, effective commencing on the Effective Date, Company shall have the exclusive right
and responsibility to manufacture and Commercialize the Products in the Territory itself or through one or more Third Parties selected by Company and shall have the responsibility in all matters relating to the manufacture and Commercialization of
the Products in the Territory. 
 (b) The Commercialization of each Product shall be governed by a commercialization plan that describes the
proposed overall program of Commercialization, including [*] (the “Commercialization Plan”). The Commercialization Plan shall be prepared by Company, acting in good faith, at least [*] prior to the expected date of Commercialization
of the first Product and submitted to MRKDG. Such Commercialization Plan shall thereafter be updated by Company, acting in good faith, at least [*]. 

  
 11 

 3.3 Company Diligence. Effective commencing on the Effective Date, Company
(either itself or through its Affiliates or sublicensees) shall use Commercially Reasonable Efforts to Develop and Commercialize [*] Products (whether as a monotherapy, Combination Product or for use in concomitant or sequential therapy with one or
more other therapeutics) in [*] Major Markets by [*]. 
 3.4 Manufacturing and Supply. 

(a) Compound Inventory. Within [*] days after the Effective Date, MRKDG shall transfer and deliver to Company the Compound Inventory.
In addition, MRKDG will use Commercially Reasonable Efforts to locate and, if available, will transfer to Company related materials for the Compounds as listed on Schedule 3.4(a). Delivery shall be [*]. It is understood between the
Parties that the Compound Inventory in the form of drug substance will be transferred from MRKDG to Company while the Compound Inventory in the form of drug product, which is stored at MRKDG’s contract manufacturing organization, will be
transferred upon Company’s request. If necessary, MRKDG will authorize its contract manufacturing organization (e.g., by letter) to transfer the Compound Inventory in the form of drug product to Company or Company’s designee. 

(b) Payment term. Payment of packaging and shipping costs and expenses shall be due within [*] after receipt by Company of a
corresponding invoice from MRKDG. 
 (c) Accompanying documentation. All Compound Inventory delivered to Company hereunder shall be
accompanied by relevant documentation including a certificate of analysis. 
 (d) No Further Supply Obligation. Other than the
obligations in Section 2.5(a) and delivery of Compound Inventory, as provided in Sections 3.4(a) and (b), MRKDG shall have no further obligation regarding the manufacturing and supply of
Compound and Company shall be solely responsible to manufacture any additional needs of Compound, or procure any additional needs of Compound from a Third Party manufacturing organization, at its own risk and cost. Upon the request of Company, MRKDG
will introduce Company to such Third Party manufacturing organization and reasonably cooperate with Company’s efforts to enter into an agreement with such Third Party (if any). 

3.5 Reporting Obligations. Company shall, [*], provide MRKDG with a written report summarizing in reasonable detail its
Development and, as applicable, Commercialization activities conducted during [*]. 
 3.6 Trademarks. Effective commencing on
the Effective Date, Company shall have the sole authority to select trademarks in connection with the Commercialization of any Product in the Field in the Territory and shall own all such trademarks. Company will not use nor seek to register,
anywhere in the Territory, any trademark that is confusingly similar to any trademark used by or on behalf of MRKDG, its Affiliates or Sublicensees in connection with any Product. 

3.7 Regulatory Matters and Pharmacovigilance. 

(a) Regulatory Filings. Effective commencing on the Effective Date, subject to Section 2.5(b), Company shall
be responsible for and shall own and maintain all Regulatory Materials and Regulatory Approvals for the Compounds and Products, including all INDs and NDAs, and shall be solely responsible for all communications with Regulatory Authorities with
respect to the Compounds and Products, sponsored by or initiated on behalf of the Company. For the Existing Clinical Trial, MRKDG and its Existing Licensee and contractors shall have the right to communicate with Regulatory Authorities with respect
to such Existing Clinical Trial as required by Applicable Law. MRKDG will keep Company promptly advised of any such communications that are material to the Research, Development, manufacture and Commercialization of Pimasertib and related Products,
based on the information available to MRKDG under the Existing License Agreement. 

  
 12 

 (b) Adverse Event Reporting. The Parties agree to comply with any and all Applicable
Laws that are applicable as of the Effective Date and thereafter during the Term in connection with a Compound/Product’s safety data collection and reporting. The sponsor of a Clinical Trial shall be solely accountable for reporting all
information required to be submitted to health authorities, ethic committees, institutional review boards and investigators as required by Applicable Laws and regulations concerning its sponsored Clinical Trial(s). Company shall be the marketing
authorization holder and shall be solely responsible for reporting all information required to be submitted to health authorities in order to maintain any health authority approval granted for the Product(s) in the Territory. If required by
Applicable Laws, the Parties (or their respective Affiliates) shall negotiate in good faith and enter into a safety data exchange agreement (such written agreement, the “Safety Data Exchange Agreement”) for exchanging adverse event
and other safety information relating to the Compounds. Unless otherwise agreed and defined in the Safety Data Exchange Agreement, until the transfer of IND No. [*] and global safety database ownership is completed, if either Party has or receives
any new safety information which may be related to the use of the Compounds or Products and which may have an impact to the reporting obligations of the other Party under Applicable Laws, such Party shall provide the other Party with all such
information in English within such reasonable timelines which enable such other Party to comply with all Applicable Laws and relevant regulations and requirements. Subject to the Existing License, Company shall have the sole decision and right to
determine whether and how to implement a recall or other market withdrawal of any Product Developed or Commercialized by Company. The information exchanged between the Parties pursuant to this Section 3.7(b) shall be
transmitted by e-mail, facsimile or overnight courier to the following address: 
 Transmission to
Company: 
 Attn: [*] Day One Biopharmaceuticals, Inc., 395 Oyster Point Boulevard, Suite 217, San Francisco, CA 94080, USA; Email: [*] 

Transmission to MRKDG: 
 [*] 

Merck KGaA, Frankfurter Strasse 250, D-64293 Darmstadt, Germany, [*] 

3.8 Applicable Laws. Company will, and will require it Affiliates, Sublicensees, and subcontractors to, comply with all
Applicable Laws in its and their Research, Development, manufacture, and Commercialization of Compound and Product, including where appropriate cGMP, GCP, and GLP (or similar standards). Without limiting the foregoing, Company will not engage
directly or indirectly, in any capacity in connection with this Agreement any Person who either has been debarred by the FDA, is the subject of a conviction described in section 306 of the FD&C Act or subject to any such similar sanction. MRKDG
will, and will require it Affiliates, the Existing Licensee and subcontractors to, comply with all Applicable Laws in the conduct of the Existing Clinical Trials, including where appropriate cGMP, GCP, and GLP (or similar standards). 

3.9 Right of Reference. MRKDG and its Affiliates hereby grant to Company and its Affiliates a right of reference to all
Regulatory Materials Controlled by MRKDG and its Affiliates relating to the Compounds or Products solely for the purpose of Company and its Affiliates to Research, Develop, manufacture and Commercialize the Compounds and Products in the Field in the
Territory. Company and its Affiliates hereby grant to MRKDG, its Affiliates and the Existing Licensee a right of reference to all Regulatory Materials Controlled by Company and its Affiliates relating to Pimasertib solely for the purpose of MRKDG,
its Affiliates and the Existing Licensee to complete the Existing Clinical Trials. Each Party will take such actions as may be reasonably requested by the other Party to give effect to the intent of this section, including providing a
cross-reference letter or similar communication to the applicable Regulatory Authority to effectuate such right of access and reference. 

  
 13 

 3.10 Existing Clinical Studies. Without limiting the generality of
Section 3.9, upon assignment of the IND No. [*] to Company according to Section 2.5(b) until completion or termination of the Existing Clinical Studies, Company will maintain the IND No. [*] and
will take all actions necessary to enable the Existing Licensee to complete the Existing Clinical Studies based on the existing cross-reference to the IND No. [*], including by providing IB updates to the Regulatory Authority and the
Existing Licensee as applicable, and maintaining the CMC-related information (e.g. module 3) comprised in IND No. [*] in such a way that MRKDG’s ability to supply its reserved inventory of Pimasertib to
Existing Licensee or the use of such Compound Inventory by Existing Licensee for purpose of the Existing Clinical Studies is not negatively affected. If Existing Licensee requires any additional quantities of Pimasertib (i.e. in excess of the amount
reserved by MRKDG) for conducting the Existing Clinical Studies or continued treatment of patients who participated in the Existing Clinical Studies after completion or termination of the Existing Clinical Studies, Company shall supply such
quantities to Existing Licensee, and shall negotiate in good faith with Existing Licensee regarding a respective supply agreement between Company and Existing Licensee. MRKDG shall use Commercially Reasonable Efforts to cause the Existing Licensee
to enter into good faith negotiations with Company regarding necessary agreements, e.g. pharmacovigilance with respect to the Existing Clinical Studies, if required by Applicable Laws. Company acknowledges and agrees that it will not use any data
that Company may receive from Existing Licensee under such pharmacovigilance agreement or otherwise, that relates to any compound or product other than Compounds and Products (in particular, Company will not process, edit, analyze or publish any
such data relating to any compound or product other than Compounds and Products), without MRKDG’s prior written consent. 
 ARTICLE 4
GOVERNANCE 
 4.1 Transition Committee. 

(a) Formation. Within [*] days after the Effective Date, the Parties will establish a transition committee (the “TC”).
The TC will be comprised of [*] representatives from each Party. In addition, each Party may invite a reasonable number of additional representatives to participate in discussions and meetings of the TC, subject to the other Party’s prior
approval. Each Party’s representatives on the TC and all other individuals participating in discussions and meetings of the TC on behalf of a Party will be subject to confidentiality and non-use
obligations with respect to information disclosed at such meeting that are no less restrictive than the provision of Article 8. [*] will designate the chairperson of the TC. The TC will conduct its responsibilities hereunder in good faith and
with reasonable care and diligence. 
 (b) Responsibilities. The TC will: 

(i) develop a process for the secure transfer of MRKDG Know-How to Company; 

(ii) review, discuss and oversee the transfer from MRKDG to Company of the MRKDG Know-How including
transfer of IND No. [*] and other items in accordance with Section 2.5; 
 (iii) review, discuss and oversee the
transfer from MRKDG to Company of the Compound Inventory in accordance with Section 3.4; and 
 (iv) perform such
other duties as are specifically assigned to the TC under this Agreement. 

  
 14 

 (c) Meetings; Minutes. 

(i) The TC will meet in person or per videoconference or conference call at least [*] following the Effective Date, and thereafter at least
[*] on such dates and at such times and places as agreed to by the members of the TC. [*]. 
 (ii) The Alliance Managers will provide the
members of the TC with draft written minutes for approval from each meeting within [*] after each such meeting. The responsibility for preparing the minutes will alternate between the Alliance Managers on a meeting-by-meeting basis. If the minutes of any meeting of the TC are not approved by the TC (with each Party’s representatives on the TC collectively having one vote) within [*] Business Days after the
meeting, the objecting Party will append a notice of objection with the specific details of the objection to the proposed minutes. 
 (d)
Decision-Making. The TC will provide a forum for the Parties to plan, oversee and monitor the Parties’ activities under this Agreement, but shall have no decision-making authority hereunder or authority to modify the terms hereunder. If
the TC is unable to reach consensus with respect to a particular matter within the scope of its planning, oversight and monitoring function for more than [*], Section 13.17 shall apply. 

(e) Adjustment of Composition and Meeting Frequency, Discontinuation. Upon completion of the transfer of the MRKDG Know-How in accordance with Section 2.5 and the transfer of Compound Inventory to Company as set forth in Section 3.4(a), the TC shall determine its composition
and meeting frequency which shall apply following such completion. The TC shall be discontinued upon completion of the Existing Clinical Studies. 

(f) Other Committees. The Parties may, by mutual agreement, form such other committees or working groups as may be necessary or
desirable to facilitate activities under this Agreement. Each such committee or working group will have no decision-making authority under this Agreement. 

4.2 Alliance Managers. Each Party will appoint a representative of such Party to act as its alliance manager under this
Agreement (each, an “Alliance Manager”). Each Party may replace its Alliance Manager at any time upon notice to the other Party. The initial Alliance Managers shall be: 

For Company: [*] 
 For MRKDG: [*]

 4.3 Specific Responsibilities. The Alliance Managers may attend meetings of the TC but may not be members of the TC. The
Alliance Managers will have the following responsibilities: 
 (a) schedule meetings of the TC and set the agenda for meetings of the TC in
each case with input from the TC members, and circulate draft written minutes; 
 (b) facilitate the flow of information and otherwise
promote communication, coordination and collaboration between the Parties; 
 (c) serve as the primary contact point between the Parties for
the purpose of providing each Party with information regarding the other Parties’ activities pursuant to this Agreement; and 
 (d)
perform such other functions as requested by the TC. 

  
 15 

 ARTICLE 5 [INTENTIONALLY OMITTED] 

ARTICLE 6 FINANCIAL TERMS 

6.1 Upfront and Near-Term Payments. In partial consideration for the grant of the rights and licenses hereunder, within [*]
after the Effective Date, Company shall pay to MRKDG the upfront non-refundable, non-creditable sum of Eight Million USD ($8,000,000.00), such amount payable by wire
transfer of immediately available funds. In addition, Company shall pay to MRKDG the following one-time, non-refundable and
non-creditable sums upon achievement of the appliable event: (i) [*] upon [*] and (ii) [*] upon [*], in each case within [*] after the achievement of the corresponding event, such amount payable by wire
transfer of immediately available funds. 
 6.2 Milestone Payments. 

(a) Effective commencing on the Effective Date, as further partial consideration for the grant of the rights and licenses hereunder, on a Product-by-Product basis, Company shall pay, or cause to be paid, to MRKDG the non-refundable milestone payments set forth below (each,
a “Regulatory Milestone Payment”) for the first Product containing or comprising Pimasertib, as well as for the first Product containing or comprising 103B (in each case whether a monotherapy or in the form of a Combination
Product or for concomitant or sequential use with other therapeutics) to achieve the corresponding Regulatory Milestone Event, provided that for the second Product (containing the respective other Compound) to achieve the corresponding Regulatory
Milestone Event, such Regulatory Milestone Payments shall be reduced by [*] 
  

							
	 #
	  	 Regulatory Milestone Event (per Product)
	  	Regulatory Milestone
Payment
(in USD)	 
	 1
	  	[*]	  	 	[*]	 
	 2
	  	[*]	  	 	[*]	 
	 3
	  	[*]	  	 	[*]	 
	 4
	  	[*]	  	 	[*]	 
	 5
	  	[*]	  	 	[*]	 

 Each of the foregoing Regulatory Milestone Payments in this Section 6.2(a) shall be payable a
maximum of [*] per Compound regardless of the number of times the applicable Regulatory Milestone Event was achieved by a Product containing or comprising the respective Compound, and no Regulatory Milestone Payment shall be due hereunder for any
subsequent or repeated achievement of such Regulatory Milestone Event by a Product containing or comprising such Compound. For the avoidance of doubt, the maximum amount payable by Company to MRKDG pursuant to this
Section 6.2(a) [*] assuming in each case that each of the Regulatory milestone events in this Section 6.2(a) were achieved. 

(b) Company shall pay to MRKDG the applicable non-refundable milestone payments set forth below (each,
a “Commercial Milestone Payment”) when cumulative Net Sales within the Territory for all Products reach each of the thresholds set forth below. 
  

					
	 Commercial Milestone Event
	  	Commercial Milestone
Payment
(in USD)	 
	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 
	 [*]
	  	 	[	*] 

  
 16 

 The achievement of a higher Commercial Milestone Event shall also trigger the payment of a lower Commercial
Milestone Event in the event such lower Commercial Milestone Event had not been triggered prior to achievement of the higher Commercial Milestone Event. For clarity, in such case both the payment of lower milestone and the higher milestone shall be
triggered. Each of the foregoing Commercial Milestone Payments in this Section 6.2(b) shall be payable a maximum of [*] as set forth in the foregoing chart regardless of the number of times the applicable Commercial
Milestone Event was achieved, and no Commercial Milestone Payment shall be due hereunder for any subsequent or repeated achievement of such Commercial Milestone Event. For the avoidance of doubt, the maximum amount payable by Company to MRKDG
pursuant to this Section 6.2(b) is [*] assuming that each of the milestone events in this Section 6.2(b) were achieved. 

(c) Company shall notify MRKDG in writing [*] after a Regulatory Milestone Event or Commercial Milestone Event has occurred. 

(d) Payment of any Regulatory Milestone Payment or Commercial Milestone Payment by Company to MRKDG shall be due within [*] upon receipt of a
corresponding invoice from MRKDG for the applicable Milestone Payment notified by Company to MRKDG pursuant to Section 6.2(c). 

6.3 Royalty. 
 (a)
Royalty Rate. Effective commencing on the Effective Date, as further consideration for MRKDG’s grant of the rights and licenses to Company hereunder, Company shall, during each applicable Royalty Term, pay to MRKDG a royalty [*]. 

[*]. 
 (b) Royalties Generally. Nothing
herein contained shall obligate Company or its Sublicensees to pay or cause to be paid to MRKDG more than one royalty on any unit of a Product. 

(c) Royalty Term. Royalties shall be payable on a
Product-by-Product and country-by-country basis from the date of First Commercial Sale of
a Product in a country until the later of (i) the expiration of the last Valid Claim of a patent included in the MRKDG Technology that covers such Product in such country; and (ii) twelve (12) years after the First Commercial Sale of such
Product in such country (the “Royalty Term”). 
 (d) Royalty Deductions. 

(i) No Valid Claim. In the event that a Product is not covered by a Valid Claim of a patent included in the MRKDG Technology in the US
before the expiration of the twelve (12) years after the First Commercial Sale in such country, then the royalties on Net Sales of such Product in the US due under Section 6.3(a) shall be reduced by [*] until the
expiration of the aforementioned twelve (12) years. In the event that a Product is not covered by a Valid Claim of a patent included in the MRKDG Technology, [*], before the expiration of the twelve (12) years after the First Commercial
Sale in such country, then the royalties on Net Sales of such Product in such country due under Section 6.3(a) shall be reduced by [*] until the expiration of the aforementioned twelve (12) years. For purposes of this
section, [*]. 
 (ii) Generic Entry. If, after entry of one or more Generic Product(s) on a country-by-country basis, the annual volume of the Product sold by or on behalf of Company, decreases by [*], as compared to the average volume of Product sold on a country-by-country basis during the [*] prior to entry of the first Generic Product, then the royalty rate set forth in Section 6.3(a) will be reduced by
[*] in such country. “Generic Product” means with respect to a Product, a Third Party product: (A) 

  
 17 

 
with the same active ingredient(s); or (B) that has obtained Regulatory Approval from the applicable Regulatory Authority by means of a procedure for establishing equivalence to the Product
or otherwise in reliance on data generated for the Product; and (C) is legally marketed in such country by or under the authority of an entity other than Company, its Affiliates or Sublicensees. 

(iii) Compulsory Licenses. If Company or its Affiliates or Sublicensees is caused by a Governmental Body to grant a compulsory license
to any Third Party with respect to a Product in a particular country or jurisdiction, then the royalty rates set forth in Section 6.3(a) on Net Sales in such country shall be reduced [*]. 

(iv) Overall Royalty Floor. Notwithstanding anything to the contrary in this Section 6.3(d), in no event
shall the royalty amounts due to MRKDG in any country in any Calendar Quarter be reduced [*] of the Royalty Rate due under 6.3(a) by operation of any of the foregoing royalty reduction mechanisms, alone or combined. 

(e) Payment of Royalties. [*], Company shall pay, or cause to be paid, to MRKDG at such place as MRKDG may from time to time designate
in writing, all royalties earned pursuant to this Section 6.3 in the preceding Calendar Quarter. All such payments shall be made in USD. 

(f) [*]. 
 6.4 Royalty
Reports; Currency Conversion; Disputes Regarding Reports. 
 (a) Commencing with the Calendar Quarter in which the First Commercial Sale
of a Product is made by Company or its Affiliate or Sublicensee, Company shall submit to MRKDG with each royalty payment a detailed, written report detailing its computation of royalties due on Net Sales in each country during each Calendar Quarter
within [*] after the end of each Calendar Quarter (and Company shall cause its Sublicensees to submit royalty reports containing the same level of detail), whereas the report shall indicate: [*]. 

(b) All payments to MRKDG hereunder shall be made by deposit of USD in the requisite amount to such bank account as MRKDG may from time to
time designate by written notice to Company. If any amounts that are relevant to the determination of amounts to be paid under this Agreement or any calculations to be performed under this Agreement are denoted in a currency other than USD, such
amounts will be converted to their USD equivalent using [*]. 
 (c) In the event of a dispute regarding the royalty reports, the Parties
shall work in good faith to resolve the dispute in good faith. If the Parties are unable to resolve the dispute within [*] following a Party’s notification of dispute, the dispute shall be submitted for decision to a certified public accounting
firm mutually selected by each Party’s certified public accountants or to such other Third Party as the Parties shall mutually agree. The decision of such expert shall be final and the costs of such decision shall [*]. Not later than [*] after
such decision and in accordance with such decision, Company shall make any additional payments to MRKDG. Any overpayment shall be credited against future amounts due by Company to MRKDG. 

6.5 Record Retention; Inspection. Company shall keep, or cause its Affiliates and Sublicensee to keep, complete and accurate
records in sufficient detail to enable Net Sales and royalties payable under Section 6.3 to be established for a period of [*] after the date that such royalties were payable. Such records shall be consistent with
Company’s normal accounting principles. At the request of MRKDG (but not more frequently than [*] an independent chartered or certified public accountant chosen by MRKDG but approved by Company (which approval shall not be unreasonably withheld
or delayed) shall be allowed access during ordinary business hours to such records pertaining to the preceding [*] solely to verify the accuracy of any payments made to MRKDG under Section 6.3. The accountant shall not
disclose to MRKDG any information other than that which should properly be contained in a report of matters relevant to Net Sales and royalty calculation and payment arising under Section 6.3. In the case of Sublicensees,
Company shall make such Sublicensees’ records available to MRKDG. Any inspection conducted under this Section 6.5 shall be [*]. 

  
 18 

 6.6 Withholding Tax. Where any sum due to be paid to MRKDG hereunder is
subject to any withholding or similar tax, Company will pay such withholding or similar tax to the appropriate Governmental Body and deduct the amount paid from the amount then due to MRKDG and within [*] transmit to MRKDG an official tax
certificate or other evidence of such withholding sufficient to enable MRKDG to claim such payment of taxes. The Parties will cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding or similar obligations in
respect of royalties and other payments made by Company to MRKDG under this Agreement. MRKDG will provide Company any tax forms that may be reasonably necessary in order for Company not to withhold tax or to withhold tax at a reduced rate under an
applicable bilateral income tax treaty. Each Party will provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes or similar obligations resulting from payments made under this
Agreement, such recovery to be for the benefit of the Party bearing such withholding tax. [*] 
 6.7 VAT. For VAT purposes
invoiced amounts are net amounts. In case payments under this Agreement are subject to VAT in Germany, VAT shall be added to the net amounts and be paid by Company to MRKDG. MRKDG shall remit such VAT to the proper tax authorities and shall
cooperate with Company in any way reasonably requested by Company, to obtain available reductions, credits, or refunds of any VAT amount attributable to services contemplated in this Agreement unless otherwise stated by local law. Company is
entitled to receive a proper invoice where any value added tax amount is shown separately, if applicable. Notwithstanding the generality of the foregoing, it is the Parties understanding that the transactions under this Agreement are not subject to
German VAT according to applicable VAT law. 
 6.8 Late Payments. All payments under this Agreement shall earn interest from
the date due until paid at a per annum rate equal to [*]. Interest will be calculated [*]. 
 ARTICLE 7 IP OWNERSHIP, INVENTIONS AND
PATENT PROSECUTION AND MAINTENANCE 
 7.1 Intellectual Property Ownership. 

(a) Effective commencing on the Effective Date, subject to the licenses granted in this Agreement, and subject to the licenses granted under
the Existing License, as between the Parties MRKDG shall retain all right, title, and interest in the MRKDG Technology. 
 (b) Subject to
the licenses granted in this Agreement, as between the Parties Company shall retain all right, title and interest in any and all other Patent Rights, Know-How, and other intellectual property rights that are
(i) in existence and owned or controlled by Company as of the Effective Date; or (ii) developed by, for, or on behalf of, Company after the Effective Date other than in course of performance of this Agreement. 

(c) All right, title, and interest in any and all other Patent Rights, Know-How, and intellectual
property rights that are developed in the course of the performance of this Agreement shall be owned (i) solely by MRKDG, if developed solely by employees, agents, or independent contractors of MRKDG; (ii) solely by Company, if developed
solely by employees, agents, or independent contractors of Company; and (iii) jointly and equally by both Parties, if developed jointly by employees, agents, or independent contractors of both Parties. Determination of ‘joint’ or
‘sole’ inventorship will be made in accordance with US patent laws. 

  
 19 

 7.2 Patent Prosecution and Maintenance of Company Patents. 

(a) Effective commencing on the Effective Date, Company shall have the right to file, prosecute, and maintain the Patent Rights owned by
Company pursuant to Section 7.1 (such Patent Rights, the “Company Patents”). 
 7.3
Patent Prosecution and Maintenance of MRKDG Patents. 
 (a) US Drug Product Listing. Company shall have the sole right to
determine which of the MRKDG Patents, if any, shall be listed for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S.CFR § 355, or any successor law in the United States, together with any
comparable laws or regulations in any other country in the Territory. The Parties shall cooperate with each other to the extent necessary to effectuate the intent of this Section 7.3(a), including, promptly upon the
other Party’s request, providing such Party with assistance necessary for such patent listing and signing all necessary documents. 

(b) Responsibility and Costs. MRKDG shall have the first right, and the obligation, to file, prosecute, and maintain MRKDG Patents.
[*]. MRKDG shall keep Company informed of the course of the filing and prosecution of MRKDG Patents or related proceedings (e.g. interferences, oppositions, re-examinations, reissues, revocations, or
nullifications) in the Territory in a timely manner, and shall take into consideration and incorporate in good faith the advice and recommendations of Company in that respect. At MRKDG’s request, Company will provide MRKDG with reasonable
assistance in prosecuting MRKDG Patents to the extent possible. 
 (c) Election not to File and Prosecute MRKDG Patents. If
MRKDG elects not to file, prosecute, or maintain a MRKDG Patent in a country or possession in the Territory, then it shall notify Company in writing at least [*] before any deadline applicable to the filing, prosecution, or maintenance of such MRKDG
Patent, as the case may be, or any other date by which an action must be taken to establish or preserve such MRKDG Patent in such country or possession. In such case, by no later than [*] before any deadline applicable to the filing, prosecution, or
maintenance of such MRKDG Patent, or any other date by which an action must be taken to establish or preserve such MRKDG Patent in such country or possession, Company shall have the right, but not the obligation, to pursue the filing or support the
continued prosecution or maintenance of such MRKDG Patent. Company may deduct [*] of any such reasonable costs incurred by Company in taking such action(s) against any amounts owed to MRKDG under Article 6. If Company does elect to take such action
in a country in the Territory, then it shall notify MRKDG of such election, and MRKDG shall reasonably cooperate with Company in this regard. [*] 

(d) Patent Term Extension. Company shall be responsible for obtaining patent term extensions wherever available for MRKDG Patents, and
for deciding which Patent Rights to extend in a country where only one patent can be extended for a given Product. MRKDG shall provide Company with all relevant information, documentation, and assistance in this respect. Any such assistance, supply
of information, and consultation shall be provided promptly and in a manner that will ensure that all patent term extensions for a Product are obtained wherever legally permissible, and to the maximum extent available. 

7.4 Enforcement of Patent Rights. 

(a) Notice. If either Party believes that a MRKDG Patent is being infringed by a Third Party or if a Third Party claims that any MRKDG
Patent is invalid or unenforceable, the Party possessing such knowledge or belief shall promptly notify the other Party and provide it with details of such infringement or claim that are known by such Party. 

(b) Right to Bring an Action. Company shall have the first right, but not the obligation, to attempt to resolve such infringement or
claim, including by filing an infringement suit, defending against such claim or taking other similar action (each, an “Action”) and to compromise or settle such infringement or claim, at its own expense. Subject to the special
circumstances of 

  
 20 

 
Section 7.6 (ANDA Filing), if Company does not take steps to abate such infringement or does not intend to prosecute or defend an Action within [*] after receiving
notice or otherwise becoming aware of such infringement or claim, Company shall promptly inform MRKDG and MRKDG then shall have the right, but not the obligation, to attempt to resolve such infringement or claim, including by filing an Action and to
compromise or settle any such infringement or claim. The Party initiating such Action shall have the sole and exclusive right to select counsel for any suit initiated by it pursuant to this Section 7.4. 

(c) Settlement. Neither Party shall settle or otherwise compromise any Action (i) by admitting that any MRKDG Patent is invalid or
unenforceable, without MRKDG’s prior written consent, and (ii) in a manner that imposes any liability or obligation on the other Party or any of its Affiliates, or materially affects the other Party’s rights hereunder, without the
other Party’s prior written consent. The settlement will be treated in accordance with the Applicable Laws of the country to which the settlement relates. 

(d) Reasonable Assistance. The Party not enforcing or defending MRKDG Patents shall provide reasonable assistance to the other Party,
including joining such Action if required by law or otherwise necessary to maintain such Action, providing access to relevant documents and other evidence and making its employees available, [*]. 

(e) Distribution of Amounts Recovered. Any amounts recovered by the Party taking an Action pursuant to this
Section 7.4 (a)-(e), whether by settlement or judgment, shall be allocated in the following order: (i) [*] (ii) [*], and (iii) the remaining amount of such recovery shall be allocated as follows: (i) [*] and (ii) [*].

 (f) Company Patents. As between the Parties, Company will have the sole right (but not the obligation) to enforce and defend the
Company Patents in the Territory, using counsel of its own choice, in its own name and under Company’s sole direction and control.

7.5 Third Party Actions Claiming Infringement. 

(a) Notice. If a Party becomes aware of any claim or action by a Third Party against either Party that claims that the Product, or its
use, Development, manufacture or Commercialization infringes such Third Party’s intellectual property rights (each, a “Third Party Action”), such Party shall promptly notify the other Party of all details regarding such claim
or action that is reasonably available to such Party. Thereafter, the Parties shall promptly meet to consider the Third Party Claim and the appropriate course of action and may, if appropriate, enter into a further joint defense agreement with
respect to the common interest privilege protecting communications regarding such Third Party Claim in a form reasonably acceptable to the Parties. 

(b) Right to Defend. Subject to the respective indemnity obligations of the Parties set forth in Article 10 and subject to
Section 7.4, and unless otherwise agreed in the joint defense agreement, each Party shall have the right, [*], but not the obligation, to defend a Third Party Action through counsel of its choosing. Each Party shall have an
equal right to participate in any settlement discussions that are held with the Third Party asserting a Third Party Claim, provided that neither Party shall enter into any settlement of any Third Party Claim that materially adversely affects the
other Party’s rights or interests (including, with respect to MRKDG, that would admit the invalidity or unenforceability of, or otherwise impair, any rights and interests in MRKDG Patents, or with respect to Company, that would admit the
invalidity or unenforceability of, or otherwise impair, any rights and interests in Company Patents) or imposes any obligation or liability on the other Party. 

7.6 Certification Under Drug Price Competition and Patent Restoration Act. Each Party shall immediately give written notice to
the other Party of any certification of which they become aware filed pursuant to 21 U.S. CFR § 355(b)(2)(A) (or any amendment or successor statute thereto) claiming that any MRKDG Patents covering a Compound or a Product, or the
manufacture or use of 

  
 21 

 
each of the foregoing, are invalid or unenforceable, or that infringement will not arise from the manufacture, use or sale of a product by a Third Party (“ANDA Filing”). In the
event of an ANDA Filing, then: (i) the time period for giving notice set forth in Section 7.4(a) shall be [*], and (ii) the time period for bringing an Action set forth in Sections 7.4(b) shall [*], or such
shorter time period as may be required in order to avoid a loss of rights under Applicable Laws. 
 ARTICLE 8 CONFIDENTIALITY 

8.1 Confidentiality Obligations. Each Party agrees that, for the Term and for [*] thereafter, such Party shall, and shall ensure
that its officers, directors, consultants, equity-investors, employees, and agents and Sublicensees shall, keep completely confidential and not publish or otherwise disclose and not use for any purpose except as expressly permitted hereunder any
Confidential Information disclosed to it by the other Party pursuant to this Agreement. The MRKDG Know-How shall be deemed the Confidential Information of both Parties. The foregoing obligations shall not
apply to any Confidential Information disclosed by a Party hereunder to the extent that the receiving Party can demonstrate that such Confidential Information: 

(a) was already known to the receiving Party or its Affiliates, other than under an obligation of confidentiality, at the time of disclosure;

 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;

 (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act
or omission of the receiving Party in breach of this Agreement; 
 (d) was subsequently lawfully disclosed to the receiving Party or its
Affiliates by a Third Party without an obligation of confidentiality other than in contravention of a confidentiality obligation of such Third Party to the disclosing Party; or 

(e) was developed or discovered by employees or agents of the receiving Party or its Affiliates who had no access to the Confidential
Information of the disclosing Party. 
 Notwithstanding the above obligations of confidentiality and
non-use, a Party may disclose information to the extent that such disclosure is reasonably necessary in connection with: 

(i) filing or prosecuting patent applications, subject to the terms of Section 7.2 or
Section 7.3; 
 (ii) prosecuting or defending litigation as permitted herein; 

(iii) with respect to Company, conducting pre-clinical studies or Clinical Trials and with respect to
MRKDG, conducting the Existing Clinical Studies; 
 (iv) with respect to Company, seeking and obtaining Regulatory Approval of any Product;
or 
 (v) complying with Applicable Laws, including securities law and the rules of any securities exchange or market on which a
Party’s securities are listed or traded. 
 In addition, in connection with any permitted filing by either Party of this Agreement with
any Governmental Body, including the U.S. Securities and Exchange Commission, the filing Party shall endeavour to obtain confidential treatment of economic, trade secret information, and such other Confidential Information as may be requested by the
other Party, and shall provide the other Party with 

  
 22 

 
the proposed confidential treatment request with reasonable time for such other Party to provide comments, and shall include in such confidential treatment request all reasonable comments of the
other Party. The disclosing Party shall, where reasonably practicable, give such advance notice to the other Party of such disclosure requirement as is reasonable under the circumstances and will use its reasonable efforts to cooperate with the
other Party in order to secure confidential treatment of such Confidential Information required to be disclosed. 
 8.2
Publications. Company shall have the right to publicly present or publish information relating to the Compounds or Products, including all Know-How generated by or on behalf of Company hereunder
(including from any Clinical Studies conducted by Company) with respect to any Product (each such proposed presentation or publication, a “Company Publication”) in accordance with this Section 8.2. Company
shall provide the MRKDG Alliance Manager with a copy of each proposed Company Publication at least [*] prior to the earlier of its presentation or intended submission for publication; provided that in the case of abstracts, this period shall be at
least [*] (such applicable period, the “Review Period”). Company agrees that it will not submit or present any such Company Publication (i) until MRKDG has provided comments in writing or by
e-mail or telefax during such Review Period on the material in such Company Publication or (ii) until the applicable Review Period has elapsed without comments from MRKDG, in which case Company may
proceed and the Company Publication will be considered approved in its entirety. If Company receives comments from MRKDG during the applicable Review Period, it shall consider the comments of MRKDG in good faith, but will retain the sole authority
to submit the manuscript for such Company Publication, provided that Company agrees to (A) delete any Confidential Information of MRKDG that MRKDG identifies for deletion in its comments (except for information has already been publicly
disclosed either prior to the Effective Date or after the Effective Date through no fault of Company or otherwise not in violation of this Agreement), and (B) delay such Company Publication for a period of up to an additional [*] after the end
of the applicable Review Period to enable MRKDG to draft and file Patent Rights with respect to any subject matter to be made public in such Company Publication and to which MRKDG has the applicable intellectual property rights to file such Patent
Rights. MRKDG and MRKDG’s licensees and contractors shall have the right to publish the results of the Existing Clinical Studies; provided, however, that MRKDG shall submit such publications to Company in advance and shall take into
account, or use Commercially Reasonable Efforts to cause its licensee or contractor, as applicable, to take into account, comments made by Company. Subject to the foregoing, with respect to any MRKDG Know-How
that is specific to a Compound or Product (to the extent such MRKDG Know-How has not been previously publicly presented or published either (i) prior to the Effective Date or (ii) after the Effective
Date in compliance with this Agreement), except as required by Applicable Law, MRKDG shall not publicly present or publish such MRKDG Know-How unless such presentation or publication is approved by Company in
writing, such approval not to be unreasonably withheld, conditioned or delayed. 
 8.3 Press Releases and Disclosure. Within
[*] after the Effective Date, the Parties will issue press releases regarding the signing of this Agreement substantially in the form attached hereto as Schedule 8.3 (whereby the date/time shall be
aligned between the Parties and which press releases shall be subject to final review and approval by the Parties prior to issuance). Except (a) as set forth in the preceding sentence and (b) as required to comply with Applicable Law
(including the rules and regulations promulgated by the United States Securities and Exchange Commission or any equivalent Governmental Body in any country in the Territory), neither Party will make any public announcement regarding this Agreement
without the prior written approval of the other Party. Notwithstanding anything to the contrary in this Article 8, the contents of any press release, presentation or other publication that has been reviewed and approved by a reviewing Party
in accordance with this Article 8 may be re-released by such reviewing Party or publishing Party without a requirement for re-approval. 

  
 23 

 ARTICLE 9 REPRESENTATIONS, WARRANTIES AND COVENANTS 

9.1 MRKDG Representations and Warranties. 

(a) MRKDG represents and warrants to Company that: 

(i) it has the full power, authority, and right to enter into this Agreement and to perform its obligations hereunder in accordance with the
terms and conditions hereof, and all requisite corporate action has been taken to authorize its execution, delivery, and performance of this Agreement; 

(ii) the execution, delivery, and performance of this Agreement by MRKDG does not breach, violate, contravene, or constitute a default under
any contract, arrangement, or commitment to which MRKDG is a party or by which it is bound, or violate any statute, law, or regulation or any court or Governmental Body having jurisdiction over MRKDG; 

(iii) all consents, approvals, and authorizations from all Governmental Bodies or other Third Parties required to be obtained by MRKDG in
connection with the execution, delivery, and performance of this Agreement have been obtained; 
 (iv)
Schedule 1.63 is a true, correct, and complete list of all MRKDG Patents; 
 (v) subject to
the licenses granted under the Existing License, it has all right, title, and interest in and to the MRKDG Technology, and neither MRKDG nor any MRKDG Affiliate has previously licensed, assigned, transferred, or otherwise conveyed any right, title,
or interest in and to the MRKDG Technology to any Third Party with respect to the Indications in the Field in any manner that would interfere with the rights granted by MRKDG to Company hereunder; 

(vi) MRKDG (and its Affiliates) does not own or Control (through license or otherwise) any (A) Patent Rights other than those Patent
Rights included within the MRKDG Patents or (B) any Know-How other than the Know-How included within the MRKDG Know-How, in
each case of (A) and (B), that is necessary to Develop, manufacture or Commercialize the Compounds or any Products (for clarity, in the form such Compounds or Products exist as of the Effective Date, as applicable); 

(vii) To MRKDG’s knowledge, (i) all MRKDG Patents are valid and enforceable Patent Rights (or in the case of patent applications,
applied for), (ii) all MRKDG Patents are filed and maintained properly and correctly and all applicable fees have been paid on or before any final due date for payment, and (iii) MRKDG has complied in all material respects with all Applicable
Law, including any duties of candor to applicable patent offices, in connection with the filing, prosecution and maintenance of the MRKDG Patents. 

(viii) as of the Effective Date, the MRKDG Technology is free and clear of any liens, charges, encumbrances, or rights of others to
possession or use. For the avoidance of doubt, this subsection (viii) is not a warranty of non-infringement or
freedom-to-operate; 
 (ix) as of the Effective Date, no
claims have been asserted, or, to MRKDG’s knowledge, threatened by any Person, nor are there any valid grounds for any claim of any such kind (A) challenging the validity, effectiveness, or ownership of MRKDG Technology, or (B) to the
effect that the use, reproduction, modification, manufacturing, distribution, licensing, sublicensing, sale, or any other exercise of rights in any of MRKDG Technology infringes or will infringe on any intellectual property right of any Person. No
such claims have been asserted or, to the knowledge of MRKDG, are threatened; 
 (x) Schedule 2.5 sets forth all of the INDs,
NDAs and Marketing Approvals for the Compounds and Products, as applicable, as of the Effective Date in the name of, or otherwise held by or on behalf of, MRKDG or any of its Affiliates in the Territory; 

  
 24 

 (xi) Neither MRKDG nor any of its Affiliates (alone or with any Third Party) is conducting
any clinical development of any Compound or Product except for the Existing Clinical Trials; 
 (xii) All research, Development (including non-clinical studies and Clinical Trials) and manufacturing activities with respect to the Compounds and Products conducted by or on behalf of MRKDG or any of its Affiliates prior to the Effective Date have been
conducted in all material respects in accordance with all Applicable Laws and, to MRKDG’s knowledge, MRKDG (and its Affiliates) has not employed or otherwise used in any capacity the services of any person or entity debarred under 21 U.S.C.
§ 335a (or foreign equivalent) in performing any such research, Development (including non-clinical studies and Clinical Trials) or manufacturing activities prior to the Effective Date, as applicable.
Neither MRKDG nor any of its Affiliates, nor, to MRKDG’s knowledge, any of its or their respective directors, officers or employees or any of its or its Affiliates’ respective agents, have made a knowingly false or fraudulent statement to
any Regulatory Authority with respect to the Development of the Compounds or Products, or knowingly failed to disclose a material fact required under Applicable Law to be disclosed to any Regulatory Authority with respect to the Development of the
Compounds or any Product; 
 (xiii) No warning letters, clinical holds or similar written notices have been issued to MRKDG or its
Affiliates with respect to any Product by any Regulatory Authority, and to MRKDG’s knowledge no warning letters or similar written notices with respect to any Product is pending or threatened; 

(xiv) No funding from any government funding source has been used in the Development or manufacture, in each case, by MRKDG (or any of its
Affiliates), of the Compounds or Products. No Development or manufacture, in each case, by or on behalf of MRKDG (or any of its Affiliates), of the Product has been conducted under any government contract, and, to MRKDG’s knowledge, no Know-How, Patent Rights or other intellectual property within the MRKDG Technology is a “subject invention” as defined under 48 CFR 27.301 (or foreign equivalent thereof); and 

(xv) to the knowledge of MRKDG, all tangible information and data provided by or on behalf of MRKDG to Company on or before the Effective
Date in contemplation of this Agreement was and is, as of the Effective Date, true and, accurate in all material respects; in addition, to the knowledge of MRKDG, MRKDG has not failed to disclose, or cause to be disclosed, any information or data
that would cause the information and data that has been disclosed to be misleading in any material respect; 
 (xvi) all Compound Inventory
delivered to Company hereunder was manufactured, stored and delivered in accordance with all Applicable Laws including cGMP applicable to the manufacturing site at the production date of such Compound Inventory, and the applicable specifications for
such Compound or Product. 
 (b) MRKDG DISCLAIMS ALL OTHER WARRANTIES EXPRESS OR IMPLIED, INCLUDING WARRANTIES TO TITLE OR NON-INFRINGEMENT, TO FREEDOM TO OPERATE, OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS OF COMPOUND/PRODUCT FOR A PARTICULAR PURPOSE. 

(c) IN NO EVENT SHALL MRKDG BE LIABLE TOWARD COMPANY FOR ANY DAMAGES OR LOSSES BASED ON FACTS OR CIRCUMSTANCES OF WHICH COMPANY WAS
ACTUALLY AWARE OF OR SHOULD HAVE BEEN AWARE OF AFTER DUE INQUIRY ON THE EFFECTIVE DATE. In particular, MRKDG shall not be liable for any damages based on facts and circumstances that were disclosed to Company or its counsel, accountants, or
other advisors with respect to the MRKDG Technology or a Product prior to the Effective Date, in particular [*]. The foregoing shall not be construed to limit MRKDG’s liability with respect to representations and warranties given by MRKDG under
Section 9.1(a). 

  
 25 

 9.2 Representations and Warranties of Company. 

(a) Company represents and warrants to MRKDG that as of the Effective Date: 

(i) it has the full power, authority, and right to enter into this Agreement and to perform its obligations hereunder in accordance with the
terms and conditions hereof, and all requisite corporate action has been taken to authorize its execution, delivery, and performance of this Agreement; 

(ii) the execution, delivery, and performance of this Agreement by Company does not breach, violate, contravene or constitute a default under
any contract, arrangement, or commitment to which Company is a party or by which it is bound, or violate any statute, law, or regulation or any court or Governmental Body having jurisdiction over Company; and 

(iii) all consents, approvals, and authorizations from all Governmental Bodies or other Third Parties required to be obtained by Company in
connection with the execution, delivery, and performance of this Agreement have been obtained. 
 (b) Company further represents and
warrants to MRKDG that: 
 (i) as of the Effective Date, all written declarations made by Company to MRKDG related to Company’s
qualifications, ability, and competence to Develop and Commercialize the Product in the Territory are materially true and correct; 
 (ii)
as of the Effective Date and at any time during the Term, Company (A) shall have and maintain facilities, personnel, experience, and expertise sufficient in quality and quantity to perform its obligations hereunder, (B) shall perform its
obligations hereunder with reasonable due care and in conformity with current generally accepted industry standards and procedures, (C) shall procure that its management establishes and maintains appropriate quality assurance, quality controls,
and review procedures to secure good standard performance of its obligations hereunder, and (D) shall procure resources sufficient to service all sale channels for the sale of a Product which has obtained Marketing Authorization and is to be
Commercialized in the Territory by Company; 
 (iii) as of the Effective Date and at any time during the Term, Company shall have
implemented sufficient security systems and intellectual property protection guidelines within its organization which are equivalent to international industry standards and qualified to avoid any unauthorized disclosure of intellectual property
rights, including Know-How, to any Third Party; 
 (iv) as of the Effective Date and at any time
during the Term, Company will procure that all data related to human samples and other Personal Data obtained in course of the Research, Development, manufacturing or Commercialization of a Compound or a Product will be obtained, processed, and
stored in compliance with all Applicable Laws, in particular with Data Protection Law, and in accordance with all medical, administrative, and ethical aspects related to the collection, procession and storage of human samples, related data, and
other Personal Data in research activities – in particular, the signature of the informed consent from the donor will be obtained, the confidentiality, and anonymization of the human samples will be procured and the personnel involved in such
activities will be authorized and will have the capacity to perform such activities, in each case in compliance with Applicable Laws; and 

(v) as of the Effective Date and at any time during the Term, Company will comply with all Applicable Laws for the care, welfare, and ethical
treatment of animals in the 

  
 26 

 
country where the Research and Development is being performed. In order to ensure proper treatment and use of animals, Company will adhere at a minimum to (A) MRKDG’s policy on the use,
care and welfare of laboratory animals, (B) MRKDG Standard on “Housing and Husbandry Practices for Common Laboratory Animals,” (C) the principle of “3Rs” – reduction, refinement, and replacement of animal studies;
(D) the principle to offer state of the art housing and husbandry conditions in the care and use of animals which means access to species appropriate food and water; access to species specific housing, including species appropriate temperature
and humidity levels; access to humane care and a program of veterinary care; animal housing that minimizes the development of abnormal behaviors; review of study design and purpose by institutional ethical review panel; commitment to minimizing pain
and distress during the studies conducted under the research plan and work is performed by demonstrable trained staff. 
 9.3
MRKDG Covenants. MRKDG hereby covenants to Company that, during the Term, 
 (a) MRKDG will not grant to any Third Party the right to
Research, Develop, or Commercialize the Compounds or Products in the Field with respect to any Indication; and 
 (b) MRKDG will not (and
shall cause its Affiliates not to) (i) take any action that would cause a lien, charge or encumbrance on any MRKDG Technology or (ii) assign, transfer, convey or otherwise grant to any Person any rights to any MRKDG Technology (or any
rights to any intellectual property that would otherwise be included in the MRKDG Technology but for such action resulting in the loss of Control of such intellectual property rights), in any manner that is inconsistent with the licenses or other
rights granted to Company under this Agreement. 
 9.4 Company Covenants. 

(a) Company hereby covenants to MRKDG that, during the Term: 

(i) Company will, and will require its Affiliates and subcontractors to comply with all Applicable Laws in its and their Research and
Development of Compounds and Products; 
 (ii) Company will only Research, Develop, or Commercialize the Compound or Product in the Field
and with respect to the Indications; 
 (iii) Company will not, and will cause its Affiliates not to (A) sell, assign, or otherwise
transfer to any Person any MRKDG Technology (or agree to do any of the foregoing) other than in connection with a Change of Control, in a manner that conflicts with the rights granted to Company hereunder, or (B) incur or permit to exist, with
respect to any MRKDG Technology, any lien, encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties, or other restrictions which conflicts with the rights granted to Company hereunder; 

(iv) Company will not engage directly or indirectly, in any capacity in connection with this Agreement any Person who either has been
debarred by the FDA, is the subject of a conviction described in Section 306 of the FD&C Act or is subject to any similar sanction; 

(v) Company will inform MRKDG promptly in writing if it or any Person engaged by Company or any of its Affiliates who is performing services
under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section 306 of the FD&C Act, or if any action, suit, claim, investigation, or legal or administrative proceeding is pending or, to
Company’s knowledge, is threatened, relating to the debarment or conviction of Company, any of its Affiliates, or any such Person performing services hereunder or thereunder; 

  
 27 

 ARTICLE 10 INDEMNIFICATION AND INSURANCE 

10.1 Indemnification by MRKDG. MRKDG shall defend, indemnify, and hold harmless Company, its Affiliates, directors, employees,
and agents (collectively, the “Licensee Indemnitees”) from and against any and all liability, damage, loss, cost, or expense (including reasonable attorney’s fees and expenses of litigation) (collectively, the
“Losses”) arising or resulting from any claims made or suits brought by Third Parties to the extent such Losses arise or result from (a) the breach of any MRKDG representations, warranties, or covenants hereunder; (b) the
gross negligence or willful misconduct of any MRKDG Indemnitee in connection with this Agreement in connection with the performance of MRKDG’s obligations or exercise of MRKDG’s rights under this Agreement; and (c) the conduct of the
Existing Clinical Trials, except to the extent such Losses arise from any claims for which Company is obligated to indemnify MRKDG Indemnitees in Section 10.2. 

10.2 Indemnification by Company. Company shall defend, indemnify, and hold harmless MRKDG, its Affiliates, directors, employees,
and agents (collectively, the “MRKDG Indemnitees”) from and against any and all Losses arising or resulting from any claims made or suits brought by Third Parties to the extent such Losses arise or result from (a) the gross
negligence or willful misconduct of Company or its Affiliates or its Sublicensees and its or their respective directors, officers, employees, and agents, in connection with the performance of Company’s obligations or exercise of Company’s
rights under this Agreement; (b) a breach of any of Company representations, warranties, or covenants hereunder (c) the activities that are actually conducted by or on behalf of Company, its Affiliates, or its Sublicensees, in particular
the handling and storage by or on behalf of Company, its Affiliates, or its Sublicensees of any chemical agents or other compounds for the purpose of conducting Research or Development by or on behalf of Company, its Affiliates, or its Sublicensees,
including any product liability, personal injury, property damage, or other damage caused thereby; or (d) any infringement of Patent Rights of any Third Party by Company, its Affiliates, or its Sublicensees with respect to any Research,
Development, or Commercialization on any Product anywhere in the world or with respect to any other activity performed under this Agreement, except to the extent such Losses arise from any claims for which MRKDG is obligated to indemnify Company
Indemnitees in Section 10.1. 
 10.3 Procedure. A Party seeking indemnification under this
Article 10 (the “Indemnified Party”) shall give prompt written notification to the other Party (the “Indemnifying Party”) of the claim for which indemnification may be sought (it being understood and agreed, however, that
the failure by a Party to give notice of such claim as provided in this Section 10.3 shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that such
Indemnifying Party is actually prejudiced as a result of such failure to give notice). Within [*] after delivery of such notification, the Indemnifying Party may, upon written notice thereof to the other Party, assume control of the defense of such
claim with counsel reasonably satisfactory to the Indemnified Party. If the Indemnifying Party does not assume control of such defense, the Indemnified Party shall control such defense and, without limiting the Indemnifying Party’s
indemnification obligations, the Indemnifying Party shall reimburse the Indemnified Party for all costs and expenses, including reasonable attorneys’ fees and disbursements, incurred by the Indemnified Party in defending itself within [*] after
receipt of any invoice therefor from the Indemnified Party. The Party not controlling such defense may participate therein at its own expense; provided, that if the Indemnifying Party assumes control of such defense and the Indemnified Party
in good faith concludes, based on written advice from outside counsel, that the Indemnifying Party and the Indemnified Party have conflicting interests with respect to such claim sufficiently adverse to make unadvisable the representation by the
same counsel of both Parties under Applicable Laws, ethical rules or equitable principles, the Indemnifying Party shall be responsible for the reasonable fees and expenses of a single counsel to the Indemnified Party in connection therewith. The
Party controlling such defense shall keep the other Party advised of the status of such claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto. The Indemnifying Party shall not agree to any
settlement of such claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto, that imposes any liability or obligation on the
Indemnified Party or that acknowledges fault by the Indemnified Party, without the prior written consent of the Indemnified Party. 

  
 28 

 10.4 Insurance. 

(a) Coverage. As of the Effective Date and at any time thereafter during the Term, each Party shall obtain and maintain [*], insurance
[*]. It is understood and agreed that this insurance shall not be construed to limit either Party’s liability with respect to its indemnification obligations hereunder. Each Party will, [*], provide to the other Party upon request, a
certificate evidencing the insurance such Party is required to obtain and keep in force under this Section 10.4. 

(b) Post-Termination Obligations. Company will maintain the insurance required under Section 10.4(a) beyond
the expiration or termination of this Agreement for a reasonable period after the period during which Company or its Affiliates or Sublicensees were Developing or Commercializing the Compound or Product, which in no event will be less than [*]. 

(c) Affiliates, Sublicensees, and Distributors. Company will require all of its Affiliates, Sublicensees, and distributors to comply
with the provisions and obligations under this Section 10.4 as if such entity were Company. 
 10.5
Consequential Damages; Limitation of Liability. EXCEPT FOR CLAIMS OF A THIRD PARTY THAT ARE SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 10, NEITHER PARTY NOR ANY OF ITS AFFILIATES WILL BE LIABLE TO THE OTHER PARTY OR ITS
AFFILIATES FOR ANY INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE, OR OTHER INDIRECT DAMAGES OR LOST OR IMPUTED PROFITS OR ROYALTIES, LOST DATA, OR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, WHETHER LIABILITY IS ASSERTED IN CONTRACT,
WARRANTY, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY, CONTRIBUTION, OR OTHERWISE ARISING OUT OF, OR RELATING TO, THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF, AND IRRESPECTIVE OF WHETHER THAT
PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. NOTHING IN THIS AGREEMENT SHALL LIMIT EITHER PARTY FROM SEEKING OR OBTAINING ANY REMEDY AVAILABLE UNDER
LAW FOR ANY BREACH OF BY THE OTHER PARTY OF ITS CONFIDENTIALITY AND NON-USE OBLIGATIONS UNDER ARTICLE 8.  

ARTICLE 11 TERM AND TERMINATION 

11.1 Term of Agreement. The term of this Agreement (the “Term”) shall commence on the Effective Date and,
unless earlier terminated as provided in this Article 11 or in Section 13.1, shall continue in full force and effect, (a) on a
Product-by-Product and country-by-country basis, until the date on which the Royalty Term
in such country with respect to such Product expires, or (b) in its entirety upon the expiration of all payment obligations under this Agreement with respect to all Products in all countries. 

11.2 Termination for Convenience by Company. Company shall have the right to terminate this Agreement in its entirety or
on a Compound-by-Compound basis at any time, for any or no reason, upon [*] advance written notice to MRKDG. 

11.3 Termination for Non-Payment. If Company has not paid the upfront payment as
provided for in Section 6.1 by the required respective payment date, MRKDG shall have the right to terminate this Agreement with immediate effect upon written notice to Company. 

  
 29 

 11.4 Termination for Breach. 

(a) Either Party may terminate this Agreement with [*] prior notice to the other Party, if the other Party breaches any material provision of
this Agreement, unless, in case that such material breach is curable by the breaching Party, the other Party cures such breach within [*] upon the date of such notice (provided that if such cure cannot be fully achieved within such [*] cure period
and the breach relates Company’s diligence obligation with regard to Development or Commercialization under this Agreement, then such cure period will be extended for an additional period of up to [*] (for a total cure period of [*]). 

(b) In the event that Company breaches its diligence obligation with regard to the Development or Commercialization under this Agreement,
MRKDG may, in its sole discretion, exercise its termination right pursuant to Section 11.4(a) either (i) in whole, (ii) with respect to one or more specific Products or Indications, or (iii) with respect to
one or more specific countries in the Territory. 
 (c) Notwithstanding the foregoing, if the breaching Party in
Section 11.4(a) disputes in good faith the existence, materiality, or failure to cure of any breach, and provides written notice to the non-breaching Party of such dispute within the
relevant cure period, the non-breaching Party will not have the right to terminate this Agreement in accordance with Section 11.4(a), unless and until (i) the relevant dispute
has been resolved in accordance with Section 13.17 and it has been finally determined that the allegedly breaching Party is in material breach of any of its obligations under this Agreement, and (ii) such Party has
failed to cure the same (which cure period shall commence following such final determination). During the time such dispute is pending, all the terms of this Agreement will remain in effect and the Parties will continue to perform all of their
respective obligations hereunder. 
 11.5 Termination for Insolvency. 

(a) If either Party makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or
substantially all of its property, files a petition under any bankruptcy or insolvency act, or has any such petition filed against it that is not discharged within [*] after the filing thereof, the other Party may terminate this Agreement in its
entirety by providing written notice of its intent to terminate this Agreement to the insolvent Party, in which case, this Agreement will terminate on the date on which the insolvent Party receives such written notice. 

(b) Rights in Bankruptcy. For purposes of Section 365(n) of the US Bankruptcy Code (the “Code”) and any
similar Applicable Law in any other jurisdiction, all rights and licenses granted under or pursuant to this Agreement by a Party are, and shall otherwise be deemed to be, for purposes of the Code or any comparable provision of any Applicable Law in
any other jurisdiction, rights to “intellectual property” (as defined in Section 101(35A) of the Code) or any comparable provision of any Applicable Law in any other jurisdiction. The Parties agree that each Party, as licensee of such
rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Code or any comparable provision of any Applicable Law in any other jurisdiction. The Parties further agree that, in the event of the
commencement of a bankruptcy proceeding by or against a Party under the Code or any comparable provision of any Applicable Law in any other jurisdiction, the other Party shall be entitled to a complete duplicate of (or complete access to, as
appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in such other Party’s possession, shall be promptly delivered to such other Party (i) upon any such commencement of a
bankruptcy proceeding upon such other Party’s written request therefor, unless such Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under clause (i), following the rejection of this
Agreement by such Party upon written request therefor by such other Party. The Parties agree that they intend the following rights to extend to the maximum extent permitted by law, including for purposes of the Code or any comparable provision of
any Applicable Law in any other jurisdiction: (a) the right of access to any intellectual property (including all embodiments thereof) of the licensor, or any Third Party with whom the licensor contracts

  
 30 

 
to perform an obligation of such licensor under this Agreement which is necessary for the Development, manufacture or Commercialization of the Product; (b) the right to contract directly
with any Third Party described in (a) to complete the contracted work and (c) the right to cure any default under any such agreement with a Third Party and set off the costs thereof against amounts payable to such licensor under this
Agreement. The provisions of this Section 11.5(b) shall be (i) without prejudice to any rights a Party may have arising under any applicable insolvency statute or other Applicable Law and (ii) effective only to
the extent permitted by Applicable Law. 
 11.6 No Challenge. In the event that Company or any of its Affiliates, anywhere in
the world, institutes, prosecutes, or otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and
Trademark Office or its foreign counterparts, any claim, demand, action, or cause of action for declaratory relief, damages, or any other remedy, or for an enjoinment, injunction, or any other equitable remedy, including any nullity suit
interference, re-examination, opposition, or any similar proceeding, alleging that any claim in a MRKDG Patent is invalid, unenforceable, or otherwise not patentable, MRKDG shall have the right to terminate
with immediate effect the license granted to Company under such challenged MRKDG Patent, upon [*] prior written notice to Company, unless Company (or its Affiliate) or such Third Party challenges any MRKDG Patent in defense of claims raised by or on
behalf of MRKDG (or its Affiliate) against Company (or its Affiliate) or such Third Party. In the event that MRKDG notifies Company in writing that any Sublicensee (or its Affiliate), anywhere in the world, institutes, prosecutes, or
otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or its foreign
counterparts, any claim, demand, action, or cause of action for declaratory relief, damages, or any other remedy, or for an enjoinment, injunction, or any other equitable remedy, including any nullity suit interference, re-examination, opposition, or any similar proceeding, alleging that any claim in a MRKDG Patent is invalid, unenforceable, or otherwise not patentable, then Company shall terminate such Sublicensee’s
sublicense in its entirety, unless such Sublicensee (or its Affiliate) or such Third Party challenges any MRKDG Patent in defense of claims raised by or on behalf of MRKDG (or its Affiliate) against such Sublicensee (or its Affiliate) or such Third
Party.  
 11.7 Competing Product Acquisition. If Company (or one of its Affiliates or its successor in interest)
acquires a Competing Product from a Third Party (“Acquired COC Program”), or undergoes a Change of Control which results in Company being controlled by an entity with a Competing Product that (i) [*] or (ii) [*] (“Acquiring
Person COC Program”), then Company shall deliver to MRKDG as soon as possible (and in any event within [*] after Company acquires such Acquired COC Program or undergoes such Change of Control) a written notification of Company’s
election, in its sole discretion, either to divest or retain all of its rights, title and interest in and to such Acquired Competing Product or Acquiring Person COC Program. [*] If Company (or its successor in interest) provides notice of its
intention to divest the Acquired Competing Product or Acquiring Person COC Program and fails to complete such divestiture within [*] after its acquisition thereof, then Company will be in material breach of this Agreement as of the expiration of
such [*] period, and notwithstanding anything to the contrary in Section 11.4, such breach shall not be capable of being cured.

11.8 Effects of Termination or Expiration. 

(a) Accrued Rights and Obligations. Termination or expiration of this Agreement shall not release either Party from its obligations
accrued prior to the effective date of termination or expiration nor deprive either Party from any rights that this Agreement has conferred on such Party. Such obligations and rights shall survive termination or expiration of this Agreement.
Termination of this Agreement by either Party shall be in addition to and not in lieu of any other remedies available to such Party, at law and in equity. 

  
 31 

 (b) Surviving Terms. Notwithstanding anything in this Agreement to the contrary, the
following provisions shall expressly survive any expiration or termination of this Agreement in accordance with their terms: Article 1 (Definitions), Article 8 (Confidentiality Obligations), Article 10
(Indemnification and Insurance), Article 13 (Miscellaneous) and Sections 6.2 (Milestone Payments (to the extent sales milestone payment obligations have accrued prior to expiration of the Royalty
Term)), 7.1 (Intellectual Property Ownership), 11.8 (Effects of Termination or Expiration) and 12.2 (Data Privacy Audits). 

(c) Ordinary Expiry. Solely if this Agreement expires pursuant to Section 11.1, as of the effective date of
the expiration of the Royalty Term with respect to a given Product and country, the license by MRKDG to Company under Section 2.1 shall convert to a fully paid, royalty free, irrevocable, perpetual, and non-exclusive license under the MRKDG Technology to Research, Develop, make, have made, use, import, export, keep, and Commercialize such Product in the Field in such country. 

(d) Consequences of Termination by Company pursuant to Sections 11.2 or 11.4 or by MRKDG pursuant to
Sections 11.3, 11.4, 11.5, 11.6, or 11.7. Upon any termination of this Agreement by Company pursuant to Sections 11.2 or 11.4 or by MRKDG pursuant to Sections 11.4,
11.5, 11.6, or 11.7 in whole: 
 (i) all licenses granted by MRKDG to Company under
Section 2.1 shall terminate, and all licenses granted by Company to MRKDG under Section 2.3 shall terminate; 

(ii) each Party shall return to the other (or at such other Party’s request, destroy) all relevant records and materials in its
possession or control containing or comprising the other Party’s Confidential Information, provided that for purpose of this Section 11.8(d)(ii), the MRKDG Know-How shall be deemed Confidential
Information of MRKDG only, and provided further, that the receiving Party may retain one copy of such Confidential Information for its archives solely to monitor compliance with its obligations herein, and provided further, that the receiving Party
shall not be required to destroy electronic files containing such Confidential Information that are made in the ordinary course of its business information back-up procedures pursuant to its electronic record
retention and destruction practices that apply to its own general electronic files and information; and 
 (iii) Company, its Affiliates,
or its Sublicensees shall cease all Commercialization of Products in the Territory in a prompt manner and in accordance with Applicable Laws; provided, however, that Company, its Affiliates, or its Sublicensee shall be entitled, during the
[*] period following such termination, to sell any commercial inventory of Products which remains on hand as of the date of the termination, so long as Company pays to MRKDG the royalties and, if applicable, and sales milestones applicable to said
subsequent sales in accordance with the terms and conditions set forth in this Agreement. Any commercial inventory remaining following such [*] period shall be offered for sale to MRKDG, at a price equal to be mutually agreed upon between the
Parties in good faith. 
 (e) Consequences of Termination in Part. Upon any termination of this Agreement by MRKDG pursuant to
Section 11.4 or 11.6 not in whole, but in part with view to one or more Products or Indications or one or more countries of the Territory, Section 11.8(d) shall apply accordingly, but solely
with view to the terminated Product or Indication or, as the case may be, the terminated countries in the Territory. 
 (f) Right to
Maintain License. Notwithstanding the foregoing, if Company would have the right to terminate this Agreement pursuant to Section 11.4 due to MRKDG’s breach of its representations and warranties [*], in lieu of such
termination Company may elect to continue this Agreement in full force and effect (in which case Section 11.8(d) would not apply), except that [*]. For clarity, Company’s election of the remedies set forth in this
Section 11.8(f) shall be without prejudice to any other remedies that Company may have under this Agreement or otherwise under law. 

  
 32 

 (g) Reversion and Reverse Royalty. Solely in the event Company terminates this
Agreement pursuant to Section 11.2 or MRKDG terminates this Agreement pursuant to Section 11.4, then on a
Product-by-Product basis and with respect to the appliable terminated countries or Indications (each a “Terminated Product”), upon MRKDG’s written
request within [*] of the effective date of such termination, Company agrees to negotiate with MRKDG in good faith, an agreement on commercially reasonable terms whereby Company would grant MRKDG a license under
Know-How and Patents Controlled by Company related directly to such Terminated Product to research, Develop, make, manufacture, have made, distribute, use, promote, market, sell, offer for sale, have sold,
export, import, and otherwise Commercialize such Terminated Product. 
 (h) Sublicensees. At each Sublicensee’s request, upon
any termination of this Agreement, a Sublicensee shall continue to have the rights and license set forth in its sublicense agreement, which agreements shall be automatically assigned to MRKDG; provided, however, that such Sublicensee is not
then in breach of any of its material obligations under its sublicense agreement; and, provided further, that the terms of the sublicense are at least as favorable to MRKDG as the ones herein. 

(i) Other Remedies. Termination of this Agreement for any reason shall not release either Party from any liability or obligation that
already has accrued prior to such termination. Termination of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect or limit, any rights or remedies that otherwise may be
available at law or in equity. 
 ARTICLE 12 DATA PRIVACY 

12.1 Compliance with Data Protection Laws. 

(a) General Compliance. 

(i) The Parties acknowledge that the Regulation (EU) 2016/679 (“EU GDPR”) will be or can become applicable to the processing
of Personal Data in connection with this Agreement and agree to process any Personal Data in accordance with Applicable Laws. Any Personal Data that(A) either Party received from the other Party, and/or (B) is processed by a Party as part of
its obligations under this Agreement shall be processed by that Party only in strict compliance with Applicable Laws and exclusively for the purposes of this Agreement. Each Party shall ensure that all Persons entrusted with the processing of
Persona Data are under the same obligation. 
 (ii) Each Party will treat the Personal Data that is processed in the performance of its
obligations in strict confidence and will only store such Personal Data for as long as it is necessary in connection with this Agreement or otherwise required by Applicable Laws. 

(b) Exchange of Personal Data Between the Parties. 

(i) The Parties acknowledge and agree that where they process Personal Data for the purposes of this Agreement, to the extent relevant under
the EU GDPR, each Party will act as an independent controller and will be solely responsible for its own processing activities. 
 (ii) If
and to the extent Personal Data is processed by or on behalf of MRKDG by Company, or by or on behalf of Company by MRKDG, so that Company or MRKDG, as the case may be, is acting as a “processor” according to the EU GDPR, a processing
agreement shall be agreed in writing by the Parties in order to comply with the requirements under the EU GDPR. 

  
 33 

 (iii) If and to the extent that the Parties jointly determine the purposes and means of
processing of Personal Data, acting as “Joint Controllers” according to the EU GDPR, the Parties shall agree in writing on a Joint Controller agreement that determines their respective responsibilities for compliance with the EU GDPR and
that shall apply in addition to the other provisions of this Clause. 
 (c) Cross-Border Transfer. Any transfer of Personal Data that
originates in the European Union to a third country outside the European Union in connection with the performance of a Party’s obligations under this Agreement shall only be made in accordance with Articles 44 to 50 of the EU GDPR and other
Applicable Laws. The Parties agree to implement appropriate safeguards in accordance with Article 46 of the EU GDPR where necessary for the transfer of Personal Data for the purposes of the collaboration under this Agreement; this includes the
obligation to enter into standard data protection clauses adopted by the European Commission in accordance with the examination procedure referred to in Article 93 (2) of the EU GDPR where necessary. 

(d) Data Processing. As at the Effective Date, it is the Parties’ mutual understanding that neither Party will act as Personal
Data processor. Should the Processing (as such term is used in the EU GDPR) of Personal Data occur, the following shall apply: 
 (i) Where
one Party consents to subcontracting by the other Party and if the Third Party contractor has access to Personal Data that is subject to this Agreement, the engaging Party shall appoint the Third Party contractor as a data processor under a contract
which shall comply with the EU GDPR and shall ensure that the Third Party contractor complies with the engaging Party’s obligations under this Clause, including, without limitation, entering into EU standard contractual clauses (if and to the
extent required). 
 (ii) Where a Party is performing services under this Agreement as Processor (as such term is used in the EU GDPR),
such Party shall promptly notify the other Party in writing after becoming aware of any breach of security leading to the accidental or unlawful destruction, loss, alteration, unauthorized disclosure of, or access to, Personal Data subject to this
Agreement (the “Data Breach”). Either Party may then request from the other Party further reasonable information about the Data Breach, including a reasonably detailed description of the Data Breach and the categories of Personal Data
affected by the Data Breach, and will work together to identify a root cause of, and to remediate such Data Breach. In furtherance of the foregoing, where (a) MRKDG becomes aware of a Data Breach, MRKDG will send an email to [*].notifying
Company without undue delay, and (b) where Company becomes aware of a Data Breach, Company will send an email to [*] notifying MRKDG without undue delay. 

12.2 Data Privacy Audits. Each Party shall have the right during the Term, and for a period of [*] following termination of this
Agreement, to conduct an investigation and audit of the other Party’s activities, books and records, to the extent they relate to that other Party’s performance under this Agreement, to verify compliance with the terms of
this Article 12; provided, however, that such books and records may not be audited more than once per Calendar Year and that such investigation or audit shall be conducted during normal business hours, upon reasonable prior notice
and performed at the sole and exclusive expense of the auditing Party. The other Party shall cooperate fully with such investigation or audit, the scope, method, nature and duration of which shall be at the sole reasonable discretion of the auditing
Party. 
 ARTICLE 13 MISCELLANEOUS 

13.1 Compliance. MRKDG intends to conduct its business in accordance with environmental, labor and social standards and to abide
by the standards set forth in the MRKDG Code of Conduct and the MRKDG Human Rights Charter (available at http://www.merckgroup.com). Company shall comply, and shall ensure that its Affiliates, Sublicensees, or subcontractors comply, in all material
respects with reasonably comparable environmental, labor, and social standards. Each Party 

  
 34 

 
further acknowledges and ensures that it and its Affiliates, sublicensees, or subcontractors are familiar with the provisions of the United States Foreign Corrupt Practices Act, the UK Bribery
Act, and applicable local bribery and corruption laws, and shall not take or permit any action that will either constitute a violation under, or cause the other Party to be in violation of, the provisions of the United States Foreign Corrupt
Practices Act, the UK Bribery Act, or other equivalent or applicable local bribery and corruption law (collectively, “Improper Conduct”). In addition to any other rights a Party may have under this Agreement, if a Party notifies the
other Party of, or if the other Party otherwise has a reasonable suspicion of, the occurrence of Improper Conduct, the Party may inspect or have inspected by an independent auditor the premises, books, and records of the other Party relevant to
Improper Conduct for the purpose of ensuring compliance with its obligations under the preceding sentence. Should a Party gain sufficient evidence that the other Party or its Affiliates, sublicensees, or subcontractors have committed or engaged in
any Improper Conduct, such Party may terminate this Agreement immediately by written notice to other Party. 
 13.2 Relationship
of the Parties. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, joint venture, or employer-employee relationship between the Parties. 

13.3 Assignment. This Agreement will not be assignable by any Party to any Third Party without the prior written consent of the non-assigning Party, except in the case of a Change of Control. Notwithstanding the foregoing, either Party may assign this Agreement or its rights and obligations under this Agreement, without the written consent
of the other Party, to an Affiliate; provided, that as a condition of such assignment, the assignee shall agree to be bound by all obligations of the assigning Party hereunder. This Agreement will be binding upon the successors and permitted
assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in
accordance with this Section 13.3 will be void. 
 13.4 Change of Control. In the event of a Change
of Control in Company, Company shall notify MRKDG within [*] after a Change of Control has occurred, or as soon as legally permissible. 

13.5 Performance and Exercise by Affiliates and Subcontractor. Each Party shall have the right to have any of its obligations
hereunder performed, or its rights hereunder exercised, by, any of its Affiliates or subcontractors and the performance of such obligations by any such Affiliate or subcontractor shall be deemed to be performance by such Party; provided,
however, that such Party shall be responsible for ensuring the performance of its obligations under this Agreement and that any failure of any Affiliate or subcontractor performing obligations of such Party hereunder shall be deemed to be a failure
by such Party to perform such obligations. For clarity, the foregoing means that each Party may designate an Affiliate or subcontractor to perform its obligations hereunder or to be the recipient of the other Party’s performance obligations
hereunder. 
 13.6 Further Actions. Each Party agrees to execute, acknowledge, and deliver such further instruments and to do
all such other acts as may be necessary or appropriate to carry out the purposes and intent of this Agreement. 
 13.7 Accounting
Procedures. Each Party shall calculate all amounts, and perform other accounting procedures required, under this Agreement and applicable to it in accordance with (a) United States generally accepted accounting principles (US GAAP) or
(b) IFRS, depending on which accounting standard is normally applied by such Party with respect to the filing of its reporting. 

13.8 Force Majeure. Neither Party shall be liable to the other for failure or delay in the performance of any of its obligations
under this Agreement for the time and to the extent such failure or delay is caused by acts of God, earthquake, riot, civil commotion, terrorism, war, strikes, or other labour disputes, fire, flood, failure or delay of transportation, default by
suppliers or unavailability of raw materials, governmental acts or restrictions, or any other reason which is beyond the control of the respective Party. The Party affected by force majeure shall provide the other Party with full particulars thereof
as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and will use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume
performance of its obligations hereunder as soon as practicable. 

  
 35 

 13.9 Representation by Legal Counsel. Each Party hereto represents that it has
been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, no presumption will exist or be implied
against the Party that drafted such terms and provisions. 
 13.10 No Implied License; No Trademark Rights. Except as set
forth herein, no right or license is granted to Company hereunder by implication, estoppel, or otherwise to any Know-How, patent, or other intellectual property right Controlled by MRKDG or its Affiliates. No
right, express or implied, is granted by this Agreement to a Party to use in any manner the name or any other trade name or trademark of the other Party in connection with the performance of this Agreement or otherwise. 

13.11 Entire Agreement; Amendments. This Agreement constitutes and contains the entire understanding and agreement of the
Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings, and agreements between the Parties, whether oral or written, regarding such subject matter. No waiver,
modification, or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party. 

13.12 Notices and Deliveries. Any notice, request, approval, or consent required or permitted to be given under this Agreement
shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by facsimile or email (receipt verified) or by express courier service (signature required) to the Party to which it is directed at its
address or facsimile number or email shown below or such other address or facsimile number or email as such Party shall have last given by notice to the other Party. 

If to MRKDG, addressed to: 

Merck KGaA 
 Frankfurter
Straße 250 
 64293 Darmstadt 

Germany 
 [*] 

with a copy, which shall not constitute notice, to: 

Merck KGaA 
 Frankfurter
Straße 250 
 64293 Darmstadt 

Germany 
 [*] 

If to Company, addressed to: 

Day One Biopharmaceuticals, Inc. 

395 Oyster Point Boulevard, Suite 217 

San Francisco, CA 94080, USA 
 [*]

  
 36 

 with a copy, which shall not constitute notice, to: 

Fenwick & West 
 801
California Street 
 Mountain View, CA 94041 USA 

[*] 
 13.13
Language. This Agreement shall be written and executed in, and all other communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version
thereof, and in the event of any conflict in interpretation between the English version and such translation, the English version shall control. 

13.14 Waiver. A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed
or construed to be a waiver of any such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations, and agreements contained in this Agreement shall be cumulative and none of them
shall be in limitation of any other remedy, right, undertaking, obligation, or agreement of either Party. 
 13.15
Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal, or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this
Agreement will be construed in such fashion as to maintain its existence, validity, and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause of portion thereof had never been contained
in this Agreement, and there will be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law. 

13.16 Governing Law. This Agreement and all disputes arising out, of or in connection with, it, including its validity and/or
termination, shall be governed by and construed in accordance with the laws [*], without giving effect to any choice of law principles that would require application of the laws of a jurisdiction outside of [*]. The Parties expressly agree that the
application of the United Nations Convention on Contracts for the International Sale of Goods (1980) is specifically excluded and shall not apply to this Agreement. 

13.17 Dispute Resolution. 

(a) General Dispute Resolution Procedure; Venue. 

(i) The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy, or claim arising from, or
related to, this Agreement or the breach hereof, including its formation, its validity, its interpretation, the enforcement of contractual rights, or obligations and/or termination (each, a “Legal Dispute”). 

(ii) If a Legal Dispute cannot be resolved within [*], any Legal Dispute hereunder shall first be presented to the Party’s Alliance
Managers for resolution. A Legal Dispute shall be referred to such Alliance Managers upon either Party providing the other Party with written notice of such referral, and such Alliance Managers shall thereafter attempt to resolve such Legal Dispute
through good faith discussions. 
 (iii) If a Legal Dispute cannot be resolved by the Alliance Managers within [*], the Legal Dispute shall
then be presented to the Party’s Senior Officers for resolution. A Legal Dispute shall be referred to such Senior Officers upon either Party providing the other Party with written notice of such referral, and such Senior Officers shall
thereafter attempt to resolve such Legal Dispute through good faith discussions. 

  
 37 

 (iv) If a Legal Dispute is not resolved by the Parties’ Senior Officers [*] of such
other Party’s receipt of such written notice, the Legal Dispute may be submitted to the courts of competent jurisdiction in [*]. 
 (b)
Injunctive Relief. Nothing contained in this Section 13.17 shall deny either Party the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency
or prospective irreparable harm, and such an action may be filed or maintained notwithstanding any ongoing discussions between the Parties. 

13.18 Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original, and
all of which together will be deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Agreement, including the signature pages with signatures (in form of handwritten,
non-certified electronic or certified electronic signatures), will be deemed an original. 

13.19 Headings; Construction; Interpretation. Headings used herein are for convenience only and shall not in any way affect the
construction of or be taken into consideration in interpreting this Agreement. The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own
choosing, and neither of which has acted under duress or compulsion, whether legal, economic or otherwise. Accordingly, the terms of this Agreement shall be interpreted and construed in accordance with the definitions for such terms provided herein
or, if no such definitions are provided, with their usual and customary meanings, and each of the Parties hereto hereby waives the application in connection with the interpretation and construction of this Agreement of any rule of Applicable Laws to
the effect that ambiguous or conflicting terms or provisions contained in this Agreement shall be interpreted or construed against the Party whose attorney prepared the executed draft or any earlier draft of this Agreement. Any reference in this
Agreement to an Article, Section, subsection, paragraph, clause, Schedule, or Exhibit shall be deemed to be a reference to any Article, Section, subsection, paragraph, clause, Schedule, or Exhibit, of or to, as the case may be, this Agreement. All
Schedules and Exhibits to this Agreement shall form an integral part of this Agreement. Except where the context otherwise requires, (a) any definition of or reference to any agreement, instrument or other document refers to such agreement,
instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements, or modifications set forth herein or therein), (b) any reference to any Applicable Laws refers
to such Applicable Laws as from time to time enacted, repealed or amended, (c) the words “herein,” “hereof,” and “hereunder,” and words of similar import, refer to this Agreement in its entirety and not to any
particular provision hereof, (d) the words “include,” “includes,” and “including” shall be deemed to be followed by the phrase “but not limited to,” “without limitation,” or words of similar
import, (e) the word “or” is used in the inclusive sense (and/or), unless otherwise indicated by the term “either/or,” and (f) the singular shall include the plural, the plural the singular, and the use of any gender
shall be applicable to all genders. 
 [Signature Page follows] 

  
 38 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and
delivered in duplicate by their duly authorized representatives with legal and binding effect as of the Effective Date. 
  

									
	DAY ONE BIOPHARMACEUTICALS, INC.	 		 	MERCK KGAA
					
	By:	 	/s/ Jeremy Bender                    	 		 	By:	 	/s/ Matthias Muellenbeck                    
					
	 Name:
	 	 Jeremy
Bender                    
	 		 	 Name:
	 	Matthias Muellenbeck                    
					
	 Title:
	 	
CEO                    
	 		 	 Title:
	 	SVP, Head Global Business Development & Alliance
		 		 		 		 	Management
					
		 		 		 	 By:
	 	/s/ Joern-Peter Halle                    
					
		 		 		 	 Name:
	 	Joern-Peter Halle                    
					
		 		 		 	 Title:
	 	Global Head of Research                    

  
 39 

 SCHEDULE 1.26 

Compounds 

  
 40 

 SCHEDULE 1.27 

Compound Inventory 

  
 41 

 SCHEDULE 1.36 

Existing Clinical Studies 

[attached] 

  
 42 

 SCHEDULE 1.63 

MRKDG Patents 

  
 43 

 SCHEDULE 2.4 

Preclinical Collaborations 

  
 44 

 SCHEDULE 2.5 

  
 45 

 SCHEDULE 3.1 

Development Plan 

  
 46 

 SCHEDULE 3.4(a) 

Related Materials 

  
 47 

 SCHEDULE 8.3 

Announcement(s) 

  
 48

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]